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EVALUATION OF CONVENTIONAL METHODS WITH 
MOLECULAR METHODS FOR THE DETECTION OF AmpC BETA 
LACTAMASE IN ENTEROBACTERIACEAE AMONG CLINICAL 
ISOLATES 
Aim of the study: 
The aim of the study is the evaluation of conventional methods with 
molecular methods for the detection of AmpC beta lactamase in 
Enterobacteriaceae among clinical isolates in Tirunelveli medical college 
hospital. 
Materials and Methods: 
The study included 50 strains of various enterobacteriaceae species 
isolated from clinical samples(Urine,pus).These isolates were screened for 
AmpC β lactamase by Disc diffusion method with Cefoxitin, Modified hodge 
test,AmpC Disc test and the genotype (BlaAmpC) was confirmed by 
Polymerase chain Reaction. 
Results: 
A total of 50 (urine[n=45], pus[n=5]) non-duplicate Cefoxitin resistant 
isolates from clinical samples which includes E.coli(n=23 ),  
Klebsiella pneumoniae(n=21 ), Klebsiella oxytoca(n= 6) were taken for this 
study. Modified Hodge test detected 16 (32%)AmpC positive isolates indicated 
by clover leaf pattern.Among these ,eight isolates(34.8%) were E.coli and 
another eight isolates(38.1) were  Klebsiella pneumoniae.  
AmpC disc test detected 18 AmpC positive isolates.Among these, ten 
isolates(43.5%) were E.coli and seven isolates(33.3%) were Klebsiella  
  
pneumoniae , one isolate(16.6%) was Klebsiella oxytoca.Real time PCR 
detected bla AmpC gene in twenty one (42%) of the 50 screen positive isolates 
.Among these,eleven isolates (47.8%)were E.coli ,10 isolates(47.6%) were 
Klebsiella pneumoniae .The sensitivity, specificity of Modified hodge test and 
AmpC disc test  were  71.42%, 96.55%, and 80.95%, 96.55% respectively. 
In AmpC-positive isolates, the resistance to third generation 
Cephalosporins was high, reaching 100% for Ceftriaxone and Ceftazidime and 
Ceftazidime+clavulanic acid and were resistant in 43%, 81%,75% and 80%  
respectively to Amikacin,Gentamicin,Nitrofurantoin and Norfloxacin . 
Conclusion: 
This study highlights the prevalence of AmpC enzyme production among 
clinical samples and also bla AmpC among AmpC producers.Modified Hodge 
test is simple to do and less costlier.AmpC disc test is to be considered as a 
diagnostic tool for AmpC detection in routine laboratory because of its high 
sensitivity, rapid and easy interpretation.In the present study, MDR among 
AmpC positive study isolates was high suggesting plasmid mediated 
spread.Dissemination of AmpC producers within the hospital or between the 
different regions of our country may become significant public health issue. 
Hence, recognition of AmpC may enhance hospital infection control rate by 
making the physician to think about the selection of suitable antibiotics. 
Key Words :  Enterobacteriaceae, AmpC, MHT, AmpC disc, test, PCR. 
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1. INTRODUCTION 
 
Gram negative rods belonging to Enterobacteriaceae are the pathogens 
frequently associated with sepsis, hospital acquired infection and infections 
involving urinary tract and gut
1
. In this family, Escherichia coli is the most 
common pathogen which causes Urinary tract infections, Appendicitis, 
Peritonitis, Post operative wound infections, Cholecystitis, Sepsis and 
Diarrhoea in infants & adults, Hemolytic uremic syndrome.
2
 Another 
significant pathogen in this family, Klebsiella pneumoniae, is the cause of 
classic lobar pneumonia. Enterobacteriaceae are sensitive to broader-
spectrum β-lactams, Quinolones, Aminoglycosides, Sulfonamides, 
Nitrofurantoin.
3
 Now a days, antibiotic resistance is more common among 
isolates from human infections
1
.In Gram-negative bacilli, the different 
mechanisms of drug resistance include Extended Spectrum Beta lactamase 
(ESBL) production, AmpC β lactamase production, porin deficiency and 
efflux mechanisms. Production of ESBLs and AmpC β-lactamases are the 
most common among the mechanisms of resistance to third generation 
Cephalosporins. Since late 1970s, AmpC β-lactamases have gained 
importance as one of the mediators of antimicrobial resistance in Gram 
negative bacilli.
4  
2 
 
They are clinically important because they award resistance to broad 
spectrum Cephalosporins, β- lactam -β lactamase inhibitor combinations 
and Aztreonam.  
AmpC β-lactamases are not inhibited by Clavulanic acid; but, they 
are inhibited by Cloxacillin.
5 
These enzymes fit in to Ambler class C 
&Bush-Jacoby-Medeiros group 1.Plasmid mediated and chromosomal or 
inducible AmpC are two different types of AmpC β-lactamases. Organisms 
such as Citrobacter freundii, Morganella morganii, Enterobacter cloaca, , 
Hafnia alvei and Serratia marcescens contain Chromosomal AmpC 
enzymes and are inducible by Cefoxitin and Imipenem but weakly induced 
by the third or fourth generation Cephalosporins.
4
 
The widespread dissemination of AmpC β lactamase genes on 
transferable plasmids is a continuing challenge.
6
Plasmid mediated ampC 
enzymes was first reported in 1988.
7
 These enzymes are present in  
K. pneumoniae, K. Oxytoca,E. coli, Enterobacter aerogenes, Salmonella 
enterica serotype Senftenberg,, Proteus mirabilis, M. morganii. They vary 
from chromosomal AmpCs in uninducible nature and in association with 
broad multidrug resistance.
8
Plasmid-mediated AmpC genes are of special 
interest because they have ability to spread from one genus or species to 
different organisms. Plasmid-mediated AmpC enzymes containing strains 
have been isolated from  hospitalized patients, and from outpatient clinics 
and rehabilitation centers.
9
 National level prevalence of plasmid mediated 
3 
 
AmpC type resistance is unknown because studies did not examined the 
strains at the molecular level which is required to reveal the various 
mechanisms involved.  
One study from the United States observed 4 per cent of the 
Escherichia coli and 7 to 8.5 per cent of the Klebsiella species contained 
plasmid mediated AmpC type enzymes(2004).
10
In a study from 
Singapore,plasmid mediated AmpC was present in 26 per cent of study 
isolates, with CMY enzymes in E.coli and DHA  enzymes  in                              
K. Pneumoniae.
11 
AmpC prevalence in Klebsiella and E coli species was 24.1%, 37.5% 
respectively in India.
12
 In another Indian study from Karnataka, prevalence 
of AmpC was 3.3 per cent in Klebsiellaisolates.
13
Detection of AmpC 
mediated resistance in Gram negative organisms poses a problem because 
the phenotypic tests may be confusing for wrong report which results in 
treatment failures. There are presently no CLSI criteria for AmpC 
detection.
7
 For initial detection, screening with cefoxitin disc is 
recommended . But, it does not consistently reveal AmpC production. Some 
of the available phenotypic tests include Modified Hodge test (Yong et al., 
2002), AmpC disc test (Sanghal et al) and inhibitor-based assays with 
boronic acid compounds (Tan et al., 2009) or cloxacillin (Brenwald et al., 
2005).
14 
Six plasmid-mediated AmpC families (MOX, CIT, DHA, EBC, 
FOX and ACC-1) were present among Gram negative organisms.
15 
4 
 
 
CMY-2, which is the most common subtype of AmpC β-lactamases , is  
present all over the world .ACT-1 is an inducible subtype common in E. coli 
and Klebsiella species from Delhi region. These Genotypes were detected 
by PCR.
16
 
Among the Enterobacteriaceae family, E. Coli and Klebsiella 
pneumoniae producing plasmid-mediated AmpC β-lactamases are 
accountable for nosocomial outbreaks of infection.
17
They have also been 
associated with treatment failure when compared with organisms without 
plasmid-mediated AmpC β-lactamases.18 Pai et al reported a treatment 
failure rate of almost 52% for AmpC-containing K. pneumoniae associated 
with bloodstream infections. Rapid detection of AmpC beta lactamases is 
important to direct proper antibiotic therapy and for suitable infection 
control measures.
19
Therefore the present study was attempted to evaluate 
and compare phenotypic methods and molecular methods for the detection 
of AmpC beta lactamase among clinical isolates of Enterobacteriaceae in 
Tirunelveli medical college hospital. 
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2. AIMS AND OBJECTIVES 
 
1. To screen the clinical isolates of Enterobacteriaceae for AmpC β 
lactamase production in Tirunelveli medical college hospital. 
2. To evaluate phenotypic methods for the identification of AmpC 
enzyme producers. 
3. To detect the prevalence of blaAmpC by PCR. 
4. To assess the antimicrobial sensitivity pattern of the clinical isolates 
of Enterobacteriaceae . 
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3. REVIEW OF LITERATURE 
 
3.1.Description of the Enterobacteriaceae family: 
Enterobacteriaceae are a huge family of Gram-negative rods and the 
members of this family are either free-living or part of the normal ﬂora of 
humans and animals
3
.The family contains 40 genus and 150 named species 
and subspecies, along with named biogroups and unnamed organisms
1
. 
3.1.1.Important Genera& species 
Escherichia coli,Klebsiella pneumoniae, Salmonella enterica S.Typhi, 
Salmonella Typhimurium, Salmonella Enteritids, Shigella, Citrobacter, 
Enterobacter, Serratia, Proteus, Providencia, Morganella, Yersinia Pestis, 
Yersinia enterocolitica, Yersinia Pseudotuberculosis are the significant 
species of Enterobacteriaceae family
2
. 
3.1.2.Clinical significance of Enterobacteriaceae: 
They produce Septicemia(50%),Urinary tract infections(70%), and 
Intestinal infections, Nosocomial infections.
1
The most common cause of 
urinary tract infections (UTIs) in both community and health care settings 
are Enterobacteriaceae .
20
 
JB Sharma et al reported that 2/3rd of the cultures from the patients 
with SSI(Surgical site infections) from North east India teaching hospital 
showed the growth of Enterobacteriaceae.
21 
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 Nosocomial sepsis in Neonates was caused by Enterobacteriaceae  
commensals  of  the newborn  intestine.
22
 
Beena antony et al isolated 18 Enterobacter Cloacae from neonates 
with septicaemic syndrome in Mueller medical college, Karnataka.
23
 
3.2.Escherichia: 
The genus consists of six species; E. Coli,Escherichia albertii, 
Escherichia blattae, Escherichia fergusonii, Escherichia hermannii, and 
Escherichia vulneris. All species have been isolated from human specimens 
except E. blattae, which is a commensal organism of cockroaches.
24
 
3.2.1.E. Coli: 
Theodore Escherich (German paediatrician) identiﬁed E. coli in his 
studies of the intestinal ﬂora of infants in 1885.Castellani and Chalmers 
denoted the genus Escherichia and identified the type species E. coli 
(1919).This is the most common causative organism in human bacterial 
infections.
2
 
3.2.2. Morpholgy: 
They are rod in shape and 2.0 and 6.0 μm in length and 1.1 and 1.5 
μm in width. All strains are motile by peritrichous ﬂagella with the 
exception of the E. coli ‘inactive‟ species. Polysaccharide capsules are 
common in E. coli. Different kinds of ﬁmbriae are present in E.coli and are 
called as organs of adhesion.
25
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3.2.3.Cell wall: 
Cell wall has an outer membrane composed of phospholipids, lipid A 
and proteins which is in turn surrounded by capsular polysaccharides.
25
 
3.2.4.Antigens in E. Coli: 
 E. coli serotyping was done by determination of the O, K, and H 
antigens. Sometimes a ﬁmbrial virulence factor is also present(F).  
3.2.5. Virulence factors:  
EPEC -Enteropathogenic E. coli : 
1. bfpA - Bundle-forming pilus   
2. dsbA- Disulﬁde isomerise. 
3. eae- Intimin 
4. per -Plasmid encoded regulator. 
5. SepA/sepB  
Verotoxigenic E. coli (VTEC) : 
1)eae -Causes intimate adherence to epithelial cells; similar to eae of EPEC  
2)vtx gene family A1B5 toxin (similar to Shiga toxin). A subunit removes 
one base speciﬁcally from eukaryotic 28S rRNA and results in inhibition of 
protein synthesis. B subunit is for binding to receptor on host cell . 
EHEC-EnteroHaemorrhagicE.Coli: 
hlyA - Enterohemolysin 
ETEC -Enterotoxigenic E. coli: 
1)LT -(Heat-labile A1B5 toxin ). 
9 
 
2)ST- heat-stable toxin . 
3)CFAs, CSs -colonization factor antigens or coli surface associated 
antigens 
25 
S.Sharma et al observed that serum resistant factor was thegeneral 
virulence factor noted in 132 (86.8%) isolates and 36 (23.7%) isolates with 
Haemolysin,42 strains (27.6%) were hydrophobic and protease was 
produced only   in 4 (6.9%) isolates of E. Coli.
26 
3.2.6. Extraintestinal infections: 
Urinary tract infections are caused by the Uropathic E.coli (UPEC) 
Appendicitis, Cholecystitis, Sepsis and Peritonitis, Post operative wound 
infections are other infections by Enterobacteriaceae.
2
 
 BATantry et al described that 1980(67%)were urine culture positive 
out of 2842 samples for Escherichia coli which is followed by Klebsiella 
pneumoniae as the commonest cause of UTI. 
27
 
 Enteropathogenic strains of E. coli have been found in the Neonatal 
Intensive Care Unit as the causative agents for neonatal sepsis.
22
 
Marlieke E.A et al estimated that more than 8,000 deaths were 
associated with Third generation Cephalosporin resistant E.Coli blood 
stream infections in the European region in 2007.
28 
Asima Banu et al reported that 253(26.8%)urine culture among the 
total 943 culture positive urine samples and 23(4.3%) out of 538 culture 
positive sputum samples, 101(6.5%) out of 1534 culture positive exudate 
10 
 
samples, 2(1.2%) out of 166 blood samples were positive for E.coli in her 
study among the clinical isolates of Bangalore Medical college
29
 
3.2.7. Intestinal infections: 
These are caused by the pathovars EPEC, ETEC, EIEC, EHEC, and 
EaggEC.  
EPEC:Enteropathogenic E.coli:
30
 
This is a causative agent of diarrheal disease in young children, 
including neonates. 
ETEC:Enterotoxigenic E.coli: 
It is a causative agent of Traveller‟s diarrhea in industrialized 
countries, causing infection in 25 to 75% of cases. 
EIEC:EnteroinvasiveE.coli:  
Genetic and clinical features of EIEC are similar with Shigella.  
EHEC:Enterohaemorrhagic E.coli.(STEC) 
These pathogens cause hemorrhagic colitis and haemolytic uremic 
syndrome (HUS). The most prominent serotype is O157:H7 . 
EAggEC:EnteroaggregativeE.coli: EAEC adheres to intestinal mucosa 
and induces toxic effects that result in diarrhoea.
30
 
Andrej et al reported that 128 (90%) from total 143 EAEC strains 
were positive for gene encode anti-aggregation protein detected by PCR 
assay .
31
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 Sanjucta Dutta detected Diarrhoeal E.Coli in 11.8% (452/3826) 
among Hospitalized Diarrheal Patients in Kolkata, India and observed that 
EAEC was more prevalent (5.7%) than ETEC (4.2%) and EPEC (1.8%) by 
Multiplex PCR assay.
32
 
3.3.Klebsiellaspecies : 
Von Frisch identified a capsulated organism from rhinoscleroma 
patient in 1882.Friedlander cultivated another organism (Friedlander‟s 
bacillus)from the  patients with pneumonia in 1883. Ozaena bacillus was 
discovered by Abel in 1896.
33
 
Non existence of motility and the occurrence of polysaccharide 
capsule are the characteristic features of the genus Klebsiella .The colonies 
have mucoid character. Total seventy capsular types have been 
identiﬁed.Pili are also present on the surface and they are helpful for 
adherence to respiratory and urinary epithelium.
3 
Klebsiella pneumoniae (K,pneumonia subspecies pneumoniae, K. 
pneumoniae subsp. Rhinoscleromatis, K. pneumoniae subsp. Ozaenae), 
Klebsiella oxytoca, Klebsiella ornitholytica, Klebsiella terrigena are the 
significant species of this family.
33
 
3.3.1. Virulence factors 
The principal virulence factor for K. pneumoniae is its polysaccharide 
capsule. Some capsule types (K1 and K2) may be more important than 
12 
 
others. Inhibition of phagocytosis is the mechanism of virulence by capsule.  
Type 1 pili is implicated in adherence to host cells.
34 
3.3.2. Clinical significance of Klebsiella species: 
K. pneumoniaeis the cause of classic lobar pneumonia. These strains 
cause wide spread colonization of hospital patients.
33
, Klebsiella species 
exihibit high MDR pattern than other species of Enterobacteriaceae.
3
 
K.oxytoca: It is an Indole positive organism discovered by Flugge in 
1886.
33
K. oxytoca is the main pathogen in long-term-care facilities. 
30
 
K. rhinoscleromatis and K. Ozaenae: Rhinoscleroma caused by K. 
Rhinoscleromatis is a slowly progressive mucosal upper respiratory 
infection. K. ozaenae causes chronic atrophic rhinitis.   
 Pneumonia,abdominal infection, UTI, surgical site infection and  
bacteremia are caused by Klebsiella species.
30
 
In one study at Maharajah‟s institute of medical sciences, 
Andhrapradesh, India- 2008 to 2010, Dr.R.Sarathbabu et al observed that 
24.36% culture were positive for klebsiella pneumoniae in sputum samples, 
20.09% in urine samples and 24.82% in pus samples.
35 
 Malik et al reported that Multi drug resistant K. pneumoniae were the 
commonest organism isolated in 30 neonates, UP, India, leading to 14.7% 
incidence of Klebsiella nosocomial infection.
36 
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Francesco Casella et al(Italy) reported that two cases of Asiatic 
patients with Klebsiella were associated liver abscess evaluated at their 
institution. 
37 
B. N. Harish et al observed that blood culture from 130 patients 
submitted from Jawaharlal Institute of Postgraduate Medical Education and 
Research (JIPMER), Pondicherry, were positive for K. Pneumoniae.
38
 
Varsha Chaudhary et alreported  klebsiella species as the causative 
agent in 1.5% of vaginitis in her study.
39 
3.4. Antimicrobial therapy: 
 Enterobacteriaceae are insusceptible to high concentrations of 
Penicillin G, Erythromycin, and Clindamycin, but they are susceptible to the 
broader-spectrum beta-lactams, Tetracycline, Chloramphenicol, 
Aminoglycosides, Sulfonamides, Quinolones, Nitrofurantoin.
3 
3.4.1.Beta – lactam antibiotics 
Beta lactam antibiotics have beta lactam ring in their primary 
structure.  
Beta – lactam drugs: 
1)Penicillins,2)Cephalosporins ,3)Monobactams ,4)Carbapenems 
Penicillins:
40 
 Penicillins are subgrouped into 
1) Penicillin G, PenicillinV.  
Figure:1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:2 
 
 
 
14 
 
2) Penicillinase resistant penicillins: Methicillin, Nafcillin, 
Oxacillin, Cloxacillin.  
3) Carboxypenicillins: Carbenicillin, Ticarcillin  
4)Aminopenicillins: Ampicillin, Amoxicillin.  
5)Ureidopenicillins: Mezlocillin, Piperacillin.  
Cephalosporins : 
  There are five generations of Cephalosporins. They are: 
 First generation: Cefazolin, Cephalothin, Cephalexin.  
 Second generation: Cefuroxime, Cefaclor, Cefamycins (Cefotetan, 
Cefoxitin ,Cefamandole).  
 Third generation: Cefotaxime, Ceftriaxone, Cefpodoxime, 
Ceftizoxime, Cefperazone, Ceftazidime.  
 Fourth generation: Cefepime, Cefpirome. 
 Fifth generation:Ceftabiprole 
Carbapenems: 
 Imipenem, Meropenem, Ertapenem are comimg under this group. 
Monobactams:  Aztreonam  
Mechanism of action: 
The binding of the beta lactam to PBPs inhibit the synthesis of cell 
wall and leads to autolysis and death of the cell.
41 
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β-LACTAMASE INHIBITORS : 
1)Clavulanic Acid  
2)Sulbactam 
3) Tazobactam 
 are examples of the β-lactamase inhibitors. 
3.4.2.Aminoglycosides: 
Gentamicin, Kanamycin, Tobramycin, Streptomycin, Netilmicin, 
Neomycin, and Amikacin are classified as Aminoglycosides. 
Mehanism of action: 
They prevent the synthesis of protein by combining with 30S 
ribosome. 
Macrolides: 
 Examples: Erythromycin, Azithromycin. 
Mehanism of action: 
It prevents the synthesis of protein by combining with 50S ribosome. 
Tetracycline: 
Mehanism of action: 
It prevents the synthesis of protein by combining with 30S ribosome 
instead of  t-RNA binding . 
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Chloramphenicol, Lincosamides, Streptogramin:   
Mehanism of action: 
They prevent the synthesis of protein by combining with 50S 
ribosome. 
Quinolones: 
e.g :Ciproﬂoxacin, Levoﬂoxacin, Gatiﬂoxacin, and Moxiﬂoxacin 
Mehanism of action: 
They  inhibit DNA gyrase (Inhibition of Replication) 
Sulfonamides : 
Mehanism of action: 
They act by inhibiting Folic acid synthesis(Inhibit Dihydro terroate 
synthetase) 
Trimethoprim act by inhibition of Folic acid synthesis(Inhibit Dihydro 
folate synthetase)  
3.5. Antibiotic resistance patterns:  
Intially, there was a negligible resistance among the species of 
Enterobacteriaceae. Now a days, antibiotic resistance in isolates of 
Enterobacteriaceae is a major hazard to victorious therapy of infection 
which is emerging in many parts of the world .
1 
3.5.1. Classification  of resistance: 
 It can be broadly divided into 
o Intrinsic resistance 
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o  Acquired resistance 
Intrinsic resistance; 
 This type of resistance is an inherited property of a species. 
Example:  
Citrobacter freundii- Cephalothin  
Citrobacter koseri -Cephalothin, Carbenicillin  
Edwardsiella tarda- Colistin 
Enterobacter cloacae- Cephalothin  
Escherichia hermannii -Ampicillin, Carbenicillin   
 Klebsiella pneumoniae- Ampicillin, Carbenicillin  
Proteus mirabilis -Polymyxins, Tetracycline, Nitrofurantoin 
Acquired resistance:  
The following are the mechanisms of acquired resistance  
 genetic mutation 
 gene transfermechanims (Transformation,conjucation,Transduction), 
 combined mutation & gene transfer methods.41 
Mutations : 
 Incorporation of incorrect nucleotides occur during DNA replication 
randomly. Normaly a mutation will cause resistance to one class of 
antimicrobial agents, however changes affecting impermeability and efflux 
may result in a multiple resistance towards many classes of antimicrobial 
agents 
42 
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Horizontal gene transfer: 
 By processes like conjugation, transformation, and transduction 
resistance genes are able to spread from one bacterium to another.    
Conjugation: 
It is a process in which genes from one bacterium are transmitted to 
another bacterium. The process involves a donor that contain a transferable 
element and a recipient that does not. The donor produces a pilus that 
attaches the two cells. The outer membrane of the two cells fuse and DNA 
can be transferred from the donor to the recipient. Both plasmids and 
chromosomal parts can be moved.   
Transformation: 
It is the uptake of naked DNA from the environment. Cell lysis will 
release fragmented DNA that naturally competent bacteria can take up. 
Typically only short DNA fragments are exchanged.    
Transduction: 
It is a mechanism in which shift of host genes between two bacterium 
by bacteriophages.
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3.5.2. Resistance elements: 
          The resistance elements are of two types namely 
o Plasmids 
o Transposons 
 
19 
 
Plasmids: 
Plasmids are genetic elements that replicate independently of the host 
chromosome. They do not have an extracellular form and exist inside cells 
as free, circular, double stranded DNA. Examples of plasmid-encoded genes 
are virulence factors and resistance genes. 
Transposons: 
These are elements of DNA with ability to move from one place to 
another within the genome. These elements are found in humans and all 
organisms. Transposases are the enzymes which promote the movement of 
DNA. Length of the transposons vary in range from about 1000 bp, only 
carrying the genes for the transposases, to larger elements harbouring other 
genes, including resistance encoding genes. 
44 
Insertion sequence (IS) elements:
 
Insertion sequence (IS) elements are the smallest type of transposons 
found in bacterial cells. Their insertion into the genome of bacteria cause 
alterations that may result in resistance to antimicrobial agents.  
3.6.Resistance mechanisms in Enterobacteriaceae:
41
 
β-lactam antibiotics: 
It includes β lactamase inactivation, alteration in PBP targets, 
impermeability. (Production of β-lactamases which destoy β-lactam ring, so 
antibiotic can‟t bind to PBP and interfere with cell wall synthesis). 
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Tetracycline: 
These are efflux, altered target, impermeability and enzymatic 
inactivation 
Chloramphenicol : 
It is by enzymatic inactivation and  impermeability 
Quinolones: 
They bring about resistance by altering target and development of  
impermeability 
Sulfonamides : 
By altering the target ,they develop resistance. 
Trimethoprim : 
Altered target, impermeability are the processes for the development of 
resistance.  
Aminoglycosides: 
 Enzymatic inactivation-Aminoglycoside modifying enzyme 
alters various sites on the aminoglycoside molecule so that the 
ability of drug to bind the ribosome is decreased. 
  Decreased uptake of aminoglycosides due to change in number 
&character of porin channels. 
3.7.Beta-lactamases:Production of β-lactamases isthe most universal Gram-
negative resistance mechanism .
44
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These are enzymes that cause hydrolysis of beta-lactam drugs. As a result 
the cell is resistant to the action of the beta lactam drugs. 
 
 In gram-negative bacteria, the beta lactam drugs enter through the 
porin channels in to the cell and gets exposed to beta-lactamases in the 
periplasmic space. Before they reach their PBP targets, the beta-lactam 
molecules are destroyed by beta-lactamases. 
The beta-lactamases are secreted extra cellularly into the surrounding 
medium by gram positive bacteria and destroy the beta-lactam molecules 
before they have a chance to enter the cell. 
3.7.1..Classification of β-Lactamases:
40
 
 Two major classifications of β- lactamases:  
1)Molecular classification (Ambler) system  
2) Functional (Bush-Jacoby) classification system.  
Molecular classification  
Based on similarities in amino acid sequence, the Ambler 
classification separates β-lactamases into four classes (A to D) . 
 A, C, and D enzymes belong to   Serine β-lactamases  
 B enzymes belongs to Metallo β lactamases  
Functional Classification   
(Bush-Jacoby classification system)  
Four groups-1,2,3,4.(Group-2: 2a, 2b,2br , 2d, 2be, 2c, and 2f ) 
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Group 1 
CEPHALOSPORINASE: 
These are not inhibited by clavulanic acid- the molecular class 
C.(AmpC Enzymes) 
Group 2  
It includes Penicillinases, cephalosporinase which are inhibited by 
clavulanic acid. There are two subclasses namely 2a and 2b. 2b is the broad 
spectrum  β- lactamases 
GROUP 2a : 
This group has penicillinases. It comes under the Molecular 
Classification A. 
BROAD-SPECTRUM (2b): 
They have the ability to inactivate penicillins and Cephalosporins .It 
belongs to the category of Molecular Class A. It is sub classified into 2be 
and 2br.2be is named as extended spectrum and 2br is called as inhibitor 
resistant. 
EXTENDED-SPECTRUM(ESBL)or2be: 
They cause hydrolysis of third-generation Cephalosporins and 
monobactams and they are subjected to inhibition by clavulanic acid. It is 
grouped under A of Molecular Classification 
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INHIBITOR-RESISTANT (2br): 
It develops reduced inhibition by clavulanic acid-susceptible to 
tazobactam. They are also placed in category of A of molecular 
classification.  
GROUP 2c: 
 They have carbenicillinase. They cause hydrolysis of 
carbenicillin.They are in category C of the molecular classification. 
GROUP 2d:- Molecular Class D or A 
There are two enzymes in this group called cloxacillinase and oxacillinase.  
CLOXACILLINASE : 
The enzyme in this group cloxacillinase inactivates cloxacillin. These 
are weakly inhibited by clavulanic acid. They belong to either  A or D of 
molecular classification. 
OXACILLINASE: 
Oxacillinase inactivates the oxazolylpenicillins like oxacillin, 
cloxacillin. Group D is their placement in molecular classification.  
GROUP 2e:- 
Cephalosporinase of this group causes hydrolysis of monobactams, 
they are inhibited by clavulanic acid .They are in category A . 
GROUP 2f: 
Carbapenamase belonging to this subtype is a serine-based enzymes.It 
stays in the group A of molecular classification. 
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Group 3: Molecular Class B  
They have Metalloenzymes.Clavulanic acidhas  no inhibitory action 
on these this enzyme.They are Zinc based beta-lactamases, these have the 
ability to hydrolyse Penicillins, Cephalosporins, and Carbapenems.  
Group 4: 
Penicillinase is the enzyme belonging to this category. They do fit 
into any category of molecular classification. Clavulanic acid cannot act on 
these enzymes also. 
3.7.2.Genetic make up of β-Lactamases:  
β-Lactamases may be chromosome, plasmid encoded enzymes and 
their production is in a constitutive or inducible manner. Integrons encoded 
enzymes are also present. Genetic elements containintegrase gene and 
antibiotic resistance genes and integration site are called Integrons
40
.  
3.7.3.Significant types of β-lactamase enzymes:  
1) ESBLs--Extended-spectrum β-lactamases  
2)Carbapenemases  
3)AmpC- 
 Plasmid-mediated 
 Chromasomally-mediated 
3.7.4. ESBL: 
ESBLs are generally Bush group 2be&Ambler class A . 
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Epidemiology 
ESBL isolates were discovered first in Western Europe in 
1980.ESBLs are mainly found in Kiebsiella pneumoniae, Kiebsiella 
oxytoca, and E.coli, butalso isolated from Enterobacter species, Salmonella 
enterica, Morganella ,Proteus rnirabilis, Serratia marcescens, and 
Pseudomonas aeruginosa. 
 Mark E. Rupp et al observed that about 40 % of Escherichia coli and 
Klebsiella pneumonia were ESBL producers  in many parts of the world.
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Arne Søraas et al reported that 342 E. coli and  17K. Pneumoniae 
among 359 urine samples were ESBL producers yielded from Vestre Viken 
Hospital Trust , South-Eastern part of Norway.
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Arif Hussain et al observed that 23% Enterobacteriaceae isolates 
were ESBL-producers .
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Substrate profile: 
ESBLs are β-lactamases that hydrolyze Penicillins, third generation 
Cephalosporins, and Monobactam and are inhibited by Clavulanate, 
Sulbactam, and Tazobactam (β lactamase inhibitors) and are encoded by 
mobile genes.
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Families of ESBL: 
There are three families(CTX-M, SHV, and TEM). 
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CTX-M β-lactamases: 
K. pneumoniae, E. coli,Citrobacter freundii, Salmonella, Shigella 
species, , Enterobacter species, and Serratia marcescens are the pathogens 
that contain CTX-M family.CTX-M-15 is the most widely distributed ESBL 
type in India.
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TEM: 
There are 130 TEM-type beta-lactamases and 50 SHV-type enzymes.  
In 1965, the TEM -1 β lactamase enzyme was first identified from an E.coli 
isolateof Temoniera patient in Greece. TEM-1 is the cause of 90% of 
Ampicillin resistance in E. coli. E. coli and K. Pneumoniae are the 
pathogens that contain TEM-type beta-lactamases . 
 SHV: 
SHVhas a similar overall Structure with TEM-1.SHV stands for sulf 
hydryl variable. K. Pneumoniae contains SHV-1 beta-lactamase which is the 
cause of  20% of Ampicillin resistance.
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Mohammed Sahid et al observed that the prevalence of blaCTX-M, 
blaTEM, and blaSHV in 28.8%, 10.9% and 13.7% isolates of 
Enterobacteriaceae by Multiplex PCR, Uttar Pradesh, India.
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3.7.5.Carbapenemases 
The  types of Carbapenemases are 
1)Klebsiella pneumoniae carbapenemases 
 
2)Serine based carbapenamases 
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3)Metallo enzymes-(IMP Type carbapenemases, VIM Type 
carbapenemases) 
4)OXA Type carbapenamases 
Klebsiella pneumoniae carbapenemases:  
Klebsiella pneumoniae carbapenemases (KPC) confer resistance to 
third and fourth generation Cephalosporins and Carbapenems. KPC-
producing Enterobacteriaceae were ﬁrst reported in North Carolina in 
1996.
51
 
Serine based carbapenamases 
Serine carbapenemases of Bush group 2f or class A type. (Sme-1, 
Sme-2, IMI-1, GES-2, and KPC-2 ) . Usually, class A carbapenemases 
hydrolyze Imipenem but are not resistant to Clavulanic acid inhibition . 
Metalloenzymes: 
 These are Class B β-Lactamases (Bush Group 3 Enzymes).These β-
lactamases require zinc for their action. Chelating agents (EDTA) prevent 
the action of Metallo enzymes. There are three sub classes. 
1)B1 enzymes (IMP-1, VIM-2, and CcrA- one or two zinc ions) 
2) B2 enzymes (e.g., CphA) - Accumulation of a second zinc ion inhibit 
their activiy. 
3)B3 enzymes (e.g., L1) need two zinc ions. The majority of metallo-β-
lactamases are chromosomally encoded. 
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Their appearance may be constitutive or inducible. The inducible 
metallo-βlactamases are seen in B. cereus, Stenotrophomonas maltophilia,  
Aeromonas hydrophila, and Aeromonas jandaei.
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VIM: 
 These metallo-β-lactamases are broad- spectrum enzymes and are 
active against most β-lactams, including Carbapenems. blaVIM is an 
integron-borne metallo- β-lactamase that is usually found in Pseudomonas 
aeruginosa isolates. This VIM metallo-β-lactamase has spread to other 
enteric bacilli (E. coli, Enterobacter aerogenes, Enterobacter cloacae, and 
Klebsiella species.). 
IMP : 
 IMP metallo-β- lactamases have been found as part of integrons in 
the following bacteria: P. aeruginosa, Pseudomonas putida, Serratia 
marcescens, Pseudomonas stutzeri, Acinetobacter baumannii, Pseudomonas 
fluorescens, 
 K. pneumoniae, K. oxytoca, E. aerogenes, and Escherichia coli 
.Recently,NDM-1 (New Delhi metallo-β-lactamase) is a class B β-lactamase 
encoded by a mobile genetic element is also emerged.
40 
  Prasanta Raghab Mohapatra et al( Chandigarh )observed that NDM-1 
isolated from Enterobacteriaceae in Guwahati, Kolkata, Hyderabad, and 
New Delhi in India suggestsextensivedistribution.
52 
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S.Nagaraj(2012)et al observed that blaNDM positiveK. pneumoniae 
isolates were 75% and 5 isolates were  blaVIM positive by PCR in south 
India.
53 
OXA Carbapenamases:
 
These Class Dβ-Lactamases are presentin Enterobacteriaceae, 
Acinetobacter species, and P. aeruginosa. These enzymes award resistance 
to variety of Penicillins.  
They are faintly inhibited by Clavulanic acid. Several OXA β-
lactamases have resemblance with an ESBL phenotype.  
3.7.6. AmpC enzymes:  
These enzymes belong to Bush-Jacoby-Medeiros group 1 and Ambler 
class C. Theseinactivate Penicillins, third generation Cephalosporins, and 
Aztreonam & Cephamycins and are resistant to inhibition by Clavulanate, 
Sulbactam, and Tazobactam (in the case of Tazobactam, the resistance to 
inhibition is usually less) but are inhibited by Cloxacillin and Phenylboronic 
acid .
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3.8.Emergence of Resistance in Escherichia coli: 
Because of inadequate and empirical treatment with commonly used 
antibiotics, E.Coli has developed resistance against these drugs. This has 
resulted in difficulty to treat urinary tract infection. 
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MS.Kumar (Hyderabad)observed that ESBL producers were present in 
19.8% of Enterobacteriaceae isolates in tertiary care hospital at 
India(2006).
54 
Asima banu et al (Bangalore) analysed that 94.2% were resistant to 
Ampicillin and least (0%) were resistant to Carbapenams followed by 
15.6% to Netilmicin among 349 isolates of E.coli in 2011.
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E.coli had a higher percentage of resistance to 
cotrimoxazole(OP76%,IP79%)followed by cephalexin(OP72%,IP81%)and 
the lowest resistance to amikacin(OP11%,IP13%)and cefixime, Klebsiella 
species had somewhatdiverse susceptibility  pattern of E coli(2012-
Kashmir) .
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3.9. Antibiotic Resistance pattern in K. Pneumoniae: 
Nosocomial outbreaks of infection in ICUs (intensive care units) was 
caused by Antimicrobial-resistant strains of K. Pneumoniae .
30
They are 
intrinsically resistant to Ampicillin. There is exchangeable resistance to 
third generation Cephalosporins because of the production of plasmid 
encoded Extended-Spectrum β- lactamases in nosocomial strains.33 
 
R.Sarathbabu et al(Andrapradesh) denoted in his study(2012) that 
mainstream of the Klebsiella species were sensitive to Amikacin and the 
sensitivity to Amikacin was 75.56% in 2008, 70.37% in 2009,and 66.67% in 
2010 for pus samples; 66.67% in 2008 and 78.31% in 2008,74.44% in 2009 
and 71.60% in 2010 for urine samples; thus showing a gradual increase in 
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resistance and decrease in sensitivity .
35
Klebsiella pneumoniae 
carbapenemase (KPC) was first described in North Carolinarecently in 
1996.
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3.10. AmpC enzymes 
These enzymes belong to Ambler class C &Bush-Jacoby-Medeiros 
group1.  
3.10.1. Substrate profile: 
These β-lactamases inactivate Penicillins, third generation 
Cephalosporins & Cephamycins and Monobactams. These enzymes are 
resistant to inhibition by Clavulanate and Tazobactam, Sulbactam (the 
resistance to inhibition is usually less in the case of Tazobactam) but are 
inhibited by Cloxacillin and Phenyl boronic acid.
40
 
3.10.2.Mechanism: 
These β-lactamases have outsized active-site cavities which may 
permit them to bind the extended-spectrum Cephalosporins. This 
conformational expansion and flexibility enhance hydrolysis of oxyimino β 
lactams. These enzymesare distinguished from class A by this “substrate-
assisted catalysis”. 
3.10.3.structural elements: 
The structural elements are similar for class A enzymes. Near the N 
terminus of a long helix, the active-site serine (Ser64) is situated and lysine 
in the next helix (Ser64-Xaa-Xaa-Lys67). Tyr-Xaa-Asn (Tyr150) is 
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considered as second element pattern. The molecular size is from 38 to 42 
kDa. 
40 
3.10.4. Epidemiology: 
The first class C β-lactamase structure determined was for the AmpC 
cephalosporinase of Citrobacter freundii, discovered by Oefner et al. The 
structures of P99 β-lactamase of Enterobacter cloacae, AmpC β-lactamase 
from E. coli, and E.nterobacter cloacae GC1 and Enterobacter cloacae 
908R β-lactamases have been identified. 
3.10.5. Repression & Expression 
 In Gram-negative bacilli producing class C enzyme, β-lactamase 
production is usually repressed. This repression has been identified first for 
Enterobacter species. The processes of cell wall production and breakdown 
are strongly correlated to Repression and activation. The repressor and the 
activator of ampC transcription  is AmpR  molecule. 
Mulveymr et al reported that E. coli isolates resistant to cefoxitin 
were  found with incorporation of IS10 and IS911 into the promoter region 
of the blaAmpC gene, leading to an over production of the enzyme in 
Canadian hospitals . 
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3.10.6. Chromosomal AmpC enzymes : 
Almost all gram-negative bacteria produce these enzymes in greater 
or lesser extent. Some pathogens do not contain this enzyme(Salmonella, 
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Klebsiella, Proteus mirabilis, Proteus vulgaris, and Stenotrophomonas 
maltophilia ). 
 Chromosomally encoded (and inducible) enzymes are present in 
clinical isolates of Citrobacter freundii, Enterobacter cloacae, Enterobacter 
aerogenes, Morganella morganii, Serratia marcescens, and Pseudomonas 
aeruginosa.
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 Expression of chromosomal AmpC in E. coli is not inducible, but 
some E. coli species constitutively express enzymes.K. Pneumoniae does 
not possess chromosomal AmpC.
56
 
V.Supriya et al(Varanasi) in her study in 2008 observed that 7% of 
Pseudomonas aeruginosa were inducible AmpC producers among the total 
of 120 isolates.
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3.10.7.Plasmid-encoded AmpC: 
The rapid global dissemination of Enterobacteriaceae harbouring 
plasmid- encoded AmpC enzymes implies a important clinical threat.
5
There 
are four groups.  
 Group 1-plasmid-encoded AmpC cephalosporinases comprise those 
which derived from the chromosomal AmpC of C. freundii.  
 Group 2 -correlated to the chromosomal AmpC of Enterobacter 
cloacae ,  
 Group 3 - related to the AmpC of P. aeruginosa 
  Group 4- enzymes fit in to the CMY-1 β-lactamase . 
34 
 
Epidemiology:  
Plasmid encoded AmpC enzymes was first reported in 1988.
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In United states, the largest outbreak was observed with MIR-1-
producing K. pneumoniae isolates from 11 patients at the Miriam Hospital 
over a period of 9 months .
59
These enzymes are present in K. pneumoniae, 
E. Coli, E. aerogenes, K. Oxytoca, Salmonella enterica serotype 
Senftenberg, Proteus mirabilis, M. Morganii.The loss of porin channels in 
clinical isolates with plasmid-encoded AmpC enzymes may result in 
resistance to carbapenems.
9
Difference between chromosomal AmpCs and 
these enzymes are its uninducible  character and  organization with broad 
multidrug resistance.
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  Xuan Qin et al (Washington) observed that blaCMY-2 was the most  
common genotype in AmpC producing in E. coli isolates.
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3.10.8.Prevalence: 
Global prevalence: 
Plasmid-encoded AmpC β-lactamases have been observed in many 
gram-negative organisms from every parts of the world. Slike polsfuss et al 
(Switzerland) observed that33 E.Coli among the total 38 isolates were 
AmpC-producing pathogens. 
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 Xuan Qin et al(Washington)observed that 
36 (0.45%) isolates among the total 8.048Enterobacteriaceaeisolates were 
AmpC producing pathogens.
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 Azza A.Elsharkawy et al( Egypt)evaluated that2.6% were pAmpC 
producers among 38 Klebsiella pneumoniae strains by phenotypic and 
Genotypic tests. 
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  Nevine Fam et al (Egypt)detected AmpC genes in 28.3% (17/60) of 
the study isolates including E. Coli and Klebsiella by PCR.
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 Chelsie et al(USA) reported that 4% were AmpC producing 
pathogens among the 120 clinical isolates comprised of K. pneumoniae,  
Klebsiella oxytoca, and E. coli isolates by PCR .
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Akujobiet al (Nigeria) reported that 56.25%of E.coli and 43.75% of 
Klebsiella isolates were AmpC producing pathogens in Nigeria in 2012.
4
 
 Hai-Fei Yang et al (2012)observed that 5 of the 146 Serratia 
marcescens isolates from 34 hospitals in Anhui, China harboured pAmpC 
genes.
64 
 One study by Fatima et al(Iran) showed that out of (73) Gram- 
negative bacteria, only 5 (6.8%) isolates produced AmpC β- lactamase in 
2012.
65 
 Şerife Altun et al(Turkey)observed that Amp-C beta-lactamase was 
present in 4 (33%), 7 (46.7%) of E. coli, Klebsiella spp respectively in 2012 
by Inhibitor based test.
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 Yusuf et al (Kano-nigeria) reported that Morganella species (50.0%),  
Enterobacter spp (18.8%), K. aerogenes(16.7%), K. pneumoniae (16.4%) , 
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P. mirabilis (15.7%) and E. coli (8.6%) were positive for AmpC enzyme 
production. 
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3.10.9. Prevalence in India:  
In 2003, based on phenotypic tests, the reports from Delhi 
showed33.3 per cent of Gram-negative bacteria (GNB) to be AmpC enzyme 
producing pathogens .
67
In 2005, the figures from Delhi showed 6.7 per cent 
of GNB were AmpC enzyme positive isolates.
68
V.Hemalatha et al described 
that the AmpC production was in 7 (9.2%) of E.coli and K.pneumoniae 
isolates from SRM University,Chennai in 2006 by Phenotypic method.
69 
Deepika et al(2007) detected that 40% of E. Coli were AmpC enzyme 
positive isolates from Subharti Medical College, Uttar Pradesh using 
Phenotypic methods.
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Parveen et al(Jawaharlal Institute of Postgraduate Medical Education 
& Research, Puducherry) concluded that plasmid-encoded AmpC genes was 
found in 92 (38.1%) clinical isolates, which included K. pneumoniae (n=32) 
and E. coli (n=60)among the 241 total isolates(E.coli-132,  K.pneumoniae- 
109  ) from five Indian hospitals detected by PCR in 2010.
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  Anand Manoharan et al(2010) in his study showed plasmid mediated 
AmpC β lactamases in 12.5 per cent isolates with 5.2 per cent of commonly 
reported genotypes  collected from five Indian tertiary care centres.
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Mohamudha Parveen R et al(2010) concluded that 23.5%of E.coli and 
74.4% of Klebsiella isolates were positive for AmpC enzymes from 
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Jawaharlal Institute of Post Graduate Medical Education and Research, 
Pondicherry.
72
    
S.Peter et al concluded that 21/51 (41%) E. coli isolates from Institute of 
Medical Microbiology, Switzerland were true AmpC producers by 
phenotypic and genotypic tests in 2011 .
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 Vijaya Shivanna et al(Andrapradesh-2011) described that E.coli 
(20.5%), K.pneumoniae (5.5%) and Acinetobacter species (3.5%) were 
AmpC positive isolates.
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 Varsha Gupta et al(2012) reported that 20%of K. pneumoniae isolates 
were AmpC producing pathogens in University of Madras.
8
Sasirekha et al 
(2013)reported that 19.8% of E.coli and 18.2% of Klebseilla strains were 
AmpC enzyme producers in Bangalore.
19 
B. L. Chaudhary et al (2013)concluded that 14(6.94%) were AmpC 
producer by confirmatory method(Inhibitor based method)among201 
klebsiella isolates collected from MGM Hospital Kamothe, Navi Mumbai.
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Rajesh Bareja et al(2013 -Hariyana) said that 18.3% of Escherichia 
coli, 13.4% of Klebsiella species were AmpC-β-lactamase producers among 
129 isolates.
76 
Sridhar Rao PN et al (Karnataka)reported that 35 (50%) E.coli isolates 
were AmpC enzyme producers among the 62 screen-positive isolates. 
77 
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3.10.10.DISTRIBUTION;  
T.y.Tan et al (singapore) observed that the preponderance of AmpC-
positive isolates were from urine cultures.
11 
Slike polsfuss et al (Switzerland) concluded that the mainstream of  
AmpC producing pathogens were isolated from urine (52.6%), wound 
(7.9%) respiratory tract (18.4%) specimens .
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 Nevine Fam et al observed that the AmpC positive isolates were 
recovered from urine specimens (63%), pus ( 17%), sputum (12%) and body 
fluids (8%). Specimens were collected from patients (21.7%) admitted in 
ICU and (16.6)attending outpatient clinic and admitted in nephrology, 
urology, surgery and gastroenterology wards (61.7 %). 
 Sasirekha et al reported that 69.3 % of the AmpC producing 
pathogens were from females than males (30.7 %)
19 
 B. L. Chaudhary et al (2013) reported that the AmpC prevalence was 
highest in Pus (52.63%) followed by ET tube (12.5%), urine (7.40%), 
sputum(7.14%).
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 Akujobiet al (Nigeria) observed that the percentage of AmpC positive 
isolates from urine samples was significantly higher than those from other 
samples. Wound samples had the least percentage distribution of the isolates 
which are pure AmpC producers (11.11%).
4
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 Smitha O. Bagali et al(Karnataka) described that 12(50%) were from 
urine specimens, 7(29%) from pus among the total 24 AmpC producing 
strains ofE. Coli.
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3.10.11.Risk factors: 
 Previous exposure to antibiotics, predominantly third generation 
Cephalosporins and Fluoroquinolones.
 
 Presence of severe disease 
 Usage of invasive medical equipment (urinary catheters, 
endotracheal tubes, and central venous lines,nasogastric feeding 
tubes )
 
 Previous surgery 
 Recent hospitalisation  
 Prolonged hospital stay 
 Intensive care units are recognised as “risk units” due to the high 
selective pressure in combination with susceptible patients.
7 
Kenneth h rond et al observed that risk factors for AmpC-producing 
species of Klebsiella pneumoniaecomprisecare in ICU, insertion of urinary 
catheter, central venous catheterization and prolonged hospital stay and 
prioruse of antimicrobial agents, mainly third generationCephalosporins and 
β- lactamase enzyme inhibitor combinations.18 
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3.10.12. Detection methods:  
Screening with Cefoxitin disc is suggested for initial detection. 
However, it does not constantly designate AmpC enzyme production. 
Kirby-bauer disc diffusion method is used to detect Cefoxitin susceptibility.  
Coudron et al worn the cut-off point for disc diffusion with Cefoxitin 
(zone diameter < 18 mm) for screening of isolates for the detection of 
AmpC enzyme production .
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Phenotypic tests: 
The modified Hodge test (Yong et al., 2002) and  AmpC disc 
test(Sinhal et al,2005),Tris-EDTA disc test (Black et al., 2005a),  modified 
three dimensional test(Vikas Manchanda et al,2002), Inhibitor-based assays 
- boronic acid compounds (Tan et al., 2009) or cloxacillin (Brenwald et al., 
2005) are available. 
14 
Modified (Cefoxitin) Hodge test: 
E.coli ATCC 25922is streaked on MHA plates as lawn culture. 
Cefoxitin (30 μg) disc arekept in the centre of the plate.Test isolateis 
streaked from periphery to the rim of disc. 3 mm or more of “diagonal” 
growth in the cloverleaf pattern is positive for AmpC production. Isolates 
that had no or minimal distortion of the cefoxitin zone are considered to be 
negative for AmpC production
 . 79
 
Paul et al reported that Sensitivity of MHT was 73%and Specificity 
of MHT was 95%.
14
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AmpC disc test(Saline disc test) 
Moistening of the sterile plain disc with 20 μl of sterile salineis done. 
Then the saline disc is inoculated with a the test organism. MHA plate with 
lawn of E.coli ATCC 25922 is then prepared. Cefoxitin discis kept on the 
MHA plate. The disc with test organism is inverted and placed close to the 
Cefoxitin disc.
78 
Interpretation: 
 After incubation, the plate is examined for indentation or flattening 
of zone margin that indicates the positive result. 
This test is easier to perform and can be used in routine microbiology 
laboratories. 
74
According to Paul et al, AmpC disc test had a sensitivity of 
86%)and a specificity of 94%.
14
 
Tris-EDTA disc test  
 The procedure is the same as Saline disc test.But Tris EDTA disc is 
used to induce AmpC enzyme production in this test.
80
Paul et al observed 
that the sensitivity of Tris-EDTA test was 97% and specificity of this test 
was  98%.
14
 
 According to Justim elley study, the sensitivity of TE inhibition disc 
test was85% and specificity  was  90%.
81 
 Modified three dimensional test:
 
Crude enzyme extract is prepared by centrifugation and repeated 
freeze–thawing of bacterial suspension. E.coli (ATCC 25922) is streaked on 
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MHA plate as lawn culture. Cefoxitin (30 mg) disc is kept in the centre of 
the plate. Linear slits (3 cm) with circular wells are made at 5 mm distance. 
The wells are encumbered with the enzyme extract in 10 μL .Incubation is 
done at 37°C overnight. Clear distortion of zone of inhibition of Cefoxitin is 
diagnostic of positive isolates. The isolates with no distortion are considered 
as Negative isolates. But this method has some limitations like requisite of a 
applicator, trouble in filling the slits, proper  incubation of the plates to 
avoid leak of the suspension.
67 
Inhibitor-based tests: 
Antibiotic discs(6 mm) are supplemented with either boronic acid 
compounds or cloxacillin which are commercially available . Inoculation of 
MH agar is done with the test isolate and both unsupplemented and 
supplemented discs are kept. Incubation done for 16–18 h at 35 oC and the 
increase in zone size around the supplemented disc compared to the 
unsupplemented disc is recorded.  Phenylboronic acid (400 μg) with 
cefoxitin (30 μg) and cloxacillin (200 μg) with cefoxitin (30 μg) are used. 
Paul et al observed that sensitivity of Phenylboronic acid (400 μg)+ 
Cefoxitin was 66% and Specificity of 98%. 
14 
Philip E. Coudron et al(virginia) observed that the  inhibitor based 
test(boronic acid) was a useful method to identify plasmid-encoded AmpC 
β-lactamase .82 
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 Noyal Mariya Joseph et al observed that the phenylboronic acid-cefoxitin 
disc test had a sensitivity of 72.9 per cent, specificity of 45.4 per cent.
83
 
Molecular methods: Multiplex PCR is the “gold standard” test for plasmid-
encoded AmpC enzyme detection by utilizing six primer pairs.
9 
Gene family of AmpC:
 
Six plasmid-encoded AmpC families (MOX, CIT, DHA, EBC, FOX 
and ACC-1) are present.
15
 CMY-type β-lactamase belonging to CIT family 
is the most general type among  them.
84
 
Escherichia coli and Klebsiella pneumoniae contain major proportion 
of plasmid-encoded AmpCgenes. These are copied from the chromosomal 
ampC genes of Enterobacter cloacae, Citrobacter freundii, Hafnia alvei and 
Morganella morganii .
56
CMY-2, which is the most common subtype of 
AmpC enzyme present all over the world and ACT-1 which is an inducible 
subtype are found  to be prevalent in E. coli and Klebsiella species .
16
 
Justin ellem et al reported that the prevalence of  plasmid mediated 
AmpC in Australia is47% for DHA and 53% for CMY type.
81
 
Tenover et al observed about 58% of the positive isolates by inhibitor 
based test were positive for the presence of  AmpC genes by  multiplex 
PCR.
85 
3.10.13. Significance of AmpC detection: 
 The presence of plasmid-encoded AmpC hide the detection of ESBL 
and KPC-producing pathogens by routine phenotypic methods. This leads to 
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problems in surveillance and infection control policies. Another problem 
encountered is the false positive susceptibility pattern of the AmpC enzyme 
producer leading to increased incidence of treatment failure. There are no 
guidelines by the CLSI to identify these enzymes.
15
Patients may receive 
inappropriate antibiotics and become seriously ill or colonised, increasing 
the possibility of cross-infection due to undetection of AmpC producers.
.86 
Hanna E. Sidjabat et al observed that symptomatic infection likely to 
occur in patients with CMY-type AmpC β-lactamase–producing E. Coli.84 
Isolates producing AmpC β enzyme are insusceptible to currently 
available β-lactamase inhibitors and resistant to additional β-lactams and 
they are feasible for budding resistance to carbapenems. AmpC carries the 
danger of extension to other organisms through plasmid arbitration within a 
hospital or geographic region.
9 
3.10.14.Treatment:
 
Carbapenems:  
It is the Choice of drug for treating the AmpC producing 
bacteria.(e.g., Imipenem, Meropenem, Ertapenem) 
Fluoroquinolones: 
If there is an in vitro susceptible to Fluoroquinolones, this drug is 
used. 
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Tigecycline  
Tigecycline is an analogue of the semisynthetic antibiotic 
Minocycline and is a broad spectrum antibiotic that acts by binding to the 
30S ribosomal subunit and by inhibition of protein translation in bacteria.  
For interpretation of sensitivity testing of Tigecycline, there is no 
CLSI guidelines.It is a another option for treatment of AmpC infections, but 
clinical experience is incomplete .
9
 
Timocillin(6-alfa-methoxy derivative of ticarcillin): 
 For this drug, clinical experience is incomplete. 
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4. MATERIALS AND METHODS 
This study was undertaken in Clinical microbiology laboratory of 
Tirunelveli Medical College, Tirunelveli for a period of one year from April 
2013 to May 2014. 
 To detect the prevalence of AmpC β lactamase production among 
Enterobacteriaceae isolates from clinical samples (Urine,pus). 
  To evaluate phenotypic methods by screening with Cefoxitin disc 
diffusion test and Modified Hodge test,AmpC disc test. 
 To identify blaAmpC gene by Real-Time PCR. 
 To find out various risk factors associated with the study group. 
 To assess the Antimicrobial susceptibility pattern of the clinical 
isolates of Enterobacteriaceae . 
4.1. Materials  
4.1.1.Sample collection and processing 
A total of 50 (urine[n=45], pus[n=5]) non-duplicate Cefoxitin 
resistant isolates from clinical samples which includes E.coli(n=23), 
Klebsiella pneumoniae (n=21 ), Klebsiella oxytoca(n= 6) were taken for this 
study.  
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The features helping in identification of E.coli are 
Morphology on Gram stained smear   
Colony appearance on nutrient agar 
Colony appearance on sheep blood agar 
Colony appearance on MacConkey agar 
Motility: Motile on Hanging drop procedure 
Positive catalase test 
Negative oxidase test 
Hugh – Leifson Oxidation – Fermentation test – Fermentative pattern 
Nitrate reduction to nitrite 
Indole production 
Negative citrateutilization test 
Negative for urea hydrolysis 
Acid/acid with gas in Triple sugar iron agar 
Methyl red- positive 
Voges – Proskaeur- negative 
Presence of lysine decarboxylase 
ONPG positive 
The Klebsiella pneumonia & Klebsiella oxytoca isolates were identified 
by:  
Morphology on Gram stained smear   
Colony appearance on nutrient agar 
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Colony appearance on sheep blood agar 
Colony appearance on MacConkey agar 
Capsule demonstration by negative staining 
Non - motile 
Positive catalase test 
Negative oxidase test 
Fermentative pattern in Hugh – Leifson Oxidation – Fermentation test 
Nitrate reduction to nitrite 
Indole not produced (Indole produced by Klebsiella oxytoca) 
Citrate utilized 
Urea hydrolyzed slowly 
Acid/acid with gas in Triple sugar iron agar 
Methyl red negative 
Voges – Proskaeur positive 
Presence of lysine decarboxylase 
ONPG positive 
4.1.2. Ethical clearance  
Because, this study involved the clinical samples from the patients, 
ethical clearance was obtained from ethical committee of Tirunelveli 
medical college before the commencement. 
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4.1.3. Proforma 
From all patients, a proforma was prepared with details like name, 
age, sex, ward, clinical diagnosis, risk factors, surgical intervention, hospital 
stay and other parameters relevant to the study. 
4.1.4. Storage of Sample : 
The Gram negative isolates were sub-cultured on to nutrient agar 
slope and stored at 2 to 8˚C. The isolates were sub-cultured every fortnight. 
4.1.5. Safety precautions: 
With aseptic precautions, all the procedures were carried out in a 
Biosafety cabinet . 
4.2. METHODS 
4.2.1.Antibioticsensitivity test 
All the strains were subjected to Disc Diffusion method(Kirby bauer 
method) to detect Cefoxitin resistance and their antibiotic sensitivity pattern. 
4.2.2.DD method 
DD method was performed by Kirby-Bauer method using Muller-
Hinton agar with the following antibiotic discs (HiMedia Laboratories, 
Mumbai, India). 
Gentamicin(10µg) 
Amikacin (30µg) 
Norfloxacin(10 µg) 
Nitrofurantoin(300 μg) 
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Ceftriaxone(30µg) 
Ceftazidime(30µg) 
 Ceftazidime with clavulanic acid(30/10 µg) 
Cefoxitin(30 µg) 
Imepenem (10µg) 
Discs were stored in a tightly sealed container with dessicant at 2°C 
to 8°C. They were allowed to equilibrate at room temperature for one to two 
hour before opening the container to minimize condensation and to reduce 
the possibility of moisture affecting the concentration of antimicrobial 
agents. 
4.2.3.Muller Hinton agar 
The ingredients of the media was purchased from HiMedia 
Laboratories, Mumbai, India .Media was prepared as per the instruction 
guidelines from manufacturers. The media was placed in a hot air oven with 
their lids a jar for 10–15 minutes, plates were dried before inoculation.  
4.2.4.Preparation of Inoculum :  
Inoculum was prepared by direct colony suspension method by taking 
four to five well isolated colonies from 18-24 hours culture, in Muller 
Hinton broth to achieve a turbid suspension. 
4.2.5.Standardization of Inoculum :  
Comparison of the inoculum suspension with 0.5 McFarland standard 
suspension by positioning the tube side by side against a white card 
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containing several horizontal black lines was done. Comparison of 
turbidities by looking at the black lines through the suspensions was done. 
After standardization, the inoculum suspension was used within 15 minutes 
of preparation. 
4.2.6.Principle of DD test: 
The principle of DD depends upon the formation of a gradient of 
antibiotic concentrations as the antibiotic agent diffuses radially into the 
agar. The drug concentration decreases at increasing distances from the disc. 
The drug concentration at a specific point in the medium is unable to inhibit 
the growth of the test organism, at a critical point, zone of inhibition is 
formed. 
4.2.7.Procedure: 
 After standardization of bacterial suspension, the suspension was 
vortexed to make sure that it was well-mixed. 
 By using a sterile swab, inoculation was done on Muller hinton agar . 
 By rotating the plate to 600, streaking was done in three directions to 
ensure uniform distribution. 
 Drying of the plate was done for three to five minutes. Antibiotic 
discs were evenly placed on the inoculated plate by using sterile 
needle mounted in a holder. 
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 15 mm from the edge of the plate, the disc was kept and the minimum 
distance of 2.5 cm was maintained between two discs. Only six discs 
were applied on a 90mm plate. 
 To ensure the adequate contact between the disc and the agar,slight 
pressure was applied on the disc and incubation was done at a 
temperature of 35˚C aerobically for 24 hours. 
 Under transmitted light, measurement of the inhibition zone was done 
by using an antibiotic scale which included the disc‟s diameter. 
4.2.8 .Interpretation of results: 
 The millimeter reading for each antibiotic agent was compared with 
that in the interpretive tables of the CLSI guidelines and results were 
interpreted as either susceptible, intermediate or resistant.  
For Cefoxitin discs, zone size of ≥ 18mm was taken as sensitive while 
zone size of ≤ 15mm was taken as resistant. (Table .1). 
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Table.1. Interpretation of Antibiotic susceptibility test 
S. 
No. 
Antibiotic disc 
Disc 
strength 
Susceptible 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
1. Amikacin 30µg ≥17 15 – 16 ≤14 
2. Gentamicin 10µg ≥15 13 – 14 ≤12 
3. 
Nitrofurontoin(uri
ne isolates) 
300µg ≥16 11 – 15 ≤10 
4. 
Norfloxacin(urine 
isolates) 
10 µg ≥17 13 – 16 ≤12 
5. Ceftriaxone 30µg ≥26 23-25 ≤22 
6. Ceftazidime 30µg ≥18 14 – 18 ≤15 
8. Cefoxitin 30µg ≥18 15 – 17 ≤15 
8. Imepenem 10 µg ≥23 20-22 ≤19 
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4.3.Phenotypic tests for detection of AmpC β-lactamases 
 Modified Hodge test, AmpC disc test were done on the Cefoxitin 
resistant strains for the identification of AmpC enzymes. 
4.3.1.Modified Hodge test: 
Principle:  
If AmpC enzyme producers are present, it permits the growth of 
Cefoxitin susceptible strain (E.coli ATCC 25922) .This can be viewed as an 
indentation  resembling cloverleaf pattern. 
Procedure: 
 0.5 ml of the 0.5 McFarl and solution was mixed with 4.5 ml of MHB 
or saline to prepare 0.5 McFarland dilution of the E.coli ATCC 
25922. 
 E.coli ATCC 25922 in 1:10 dilution was streaked on MHA plates as 
lawn culture.  
 Cefoxitin (30 mg) disc was kept in the middle of the plate. Test 
isolate was streaked from periphery to the rim of disc and incubated.  
 3 mm or more of “diagonal” growth in the cloverleaf pattern was 
positive for AmpC production. Isolates that had no or minimal 
distortion of the Cefoxitin zone were considered to be negative for 
AmpC production. On a single plate with one drug, four organisms 
can be tested. 
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4.3.2.AmpC disc Test:  
 Moistening of the sterile plain disc with 20 μl of sterile saline was 
done. 
 
 Then the saline disc was inoculated with the test organism.  
 MHA plate with lawn of E.coli ATCC 25922 was prepared.  
 Cefoxitin disc was kept on the MHA plate.  
 The disc with test organism was inverted and placed close to the 
Cefoxitin disc.
 
Interpretation:   
After incubation, the plate was examined for indentation or flattening 
of zone margin that indicates the positive result. Negative result was 
indicated by absence of indendation. 
4.4.Real-Time PCR  
The Cefoxitin resistant isolates were further tested for blaAmpC gene 
by Real-Time PCR by the kit purchased from Helini Biomolecules, 
Chennai, India and procedure followed according to the manufacturer‟s 
instructions.   
4.4.1. Safety precautions 
All the procedures were done in a Biosafety cabinet Level-2 with 
aseptic precautions. 
4.4.2.Equipments 
Refrigerated centrifuge 
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Vortex mixer 
Thermo cycler (Biorad CFX 96) 
Computer for data storage 
4.4.3.DNA extraction 
Each spin column(silica based) was recovered up to 20µg of DNA 
and yielded purified DNA of more than 30 kb in size. Isolated DNA was 
used directly for PCR reaction. 
Components of extraction 
Phosphate buffered saline 
Binding buffer  
Digestion buffer 
Proteinase K 
Lysozyme 
Internal control template 
Isopropanol 
70%Ethanol 
Elution buffer 
Spin columns with collection tube 
Storage and stability 
The kit was stored at 37˚C.Proteinase K and Lysozyme was stored at -
20˚C. 
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4.4.4.Sample preparation  
Four to five colonies of Enterobactericeae isolate was inoculated into 
1.5 ml of normal saline in a 2ml of microcentrifuge tube. Centrifugation was 
done for five minutes at 8000 rotations per minute. After discarding the 
supernatant, the remaining bacterial pellet was used. 
4.4.5.Principle of extraction 
Lysis of cells was done using Proteinase K and chaotropic salt was 
used for inactivation of nucleases. Nucleic acids of the bacterial cells have 
the property to bind to glass fibres in the spin column. In a series of rapid 
“wash and spin” steps, bound nucleic acid are purified to take away other 
contaminants of the cells. Nucleic acids were removed from the glass fibre 
by the process of salt elution. The above procedure has an advantage of 
rapid purification without using organic solvent extractions and DNA 
precipitation. 
4.4.6. Extraction procedure                                                    
 All the steps were done at room temperature. 
 The bacterial pellet was suspended in 200µl of phosphate buffered 
saline and dislodged the pellet by brief vortex for 30 seconds. 
 180µl of Digestion buffer and 20µl Lysozyme were added to the 
pellet and brief vortex done for 10 seconds. 
 Incubation done at 370c for 15 mts.  
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 Binding buffer of 200µl and 20µl of proteinase K& 5µl of internal 
control template was added to the suspension and incubated at 56°C 
for 15 minutes in a water bath. 
 300µl of Isopropanol was added and this was mixed by inverting 
several times. 
 Entire sample was pipetted into a spin column. 
 Centrifugation was done for three times at 12000 rpm and about 
500µl of 70%Ethanol was added between centrifugation after 
discarding the flow through. Finally one more centrifugation at 
13,000 rpm to discard the residual ethanol. The spin column was 
transferred to a fresh 1.5ml microcentrifuge tube. 
 75µl of the Elution buffer (pre-warmed to 56˚C) was added to the 
centre of the spin column membrane. Care was taken not to touch the 
membrane with pipette tip. 
 It was incubated for two minutes at room temperature and centrifuged 
for one minute at 13,000 rpm. 
 The spin column was discarded and purified DNA was stored at -
20°C. 
4.4.7. PCR amplification   
Key ingredients for amplification:  
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 Probe PCR Mastermix 
The probe mix contains the essential components for PCR 
amplification like DNA polymerase and deoxynucleotides. 
Bla AmpC (CMY-2) primer & probe mix 
The blaAmpC (CMY-2)primer & probe mix consists of TaqMan probe 
which is fluorescent labelled with FAM, forward primer and reverse primer. 
Forward primer- 5‟-CGGTGAAACCCTCAGGAATGAGTT-3‟ 
Reverse Primer- -  5‟-GCGGAACCGTAATCCAGGTAT-3‟ 
eddProbe - -  5‟-ACGAAGAGGCAATGACCAGGACGC-3‟ 
Internal Control template             
The internal control template consists of TaqMan probe which is 
fluorescent labelled with HEX, forward primer and reverse primer. The 
reason for adding the internal control is to make sure that PCR inhibitors are 
not present in the extracted sample DNA and the performance of PCR mix 
ingredients are good. When there is no amplification in internal control, it 
indicates that PCR inhibitors are present in the sample and efficiency of the 
nucleic acid purification is not optimum. It helps to rule out false negative 
results. 
AmpC positive template 
 To be used for positive control mix. 
Nuclease free water 
It was used in negative control mix. 
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PCR amplification kit storage 
The kit was stored at -20˚C. 
bla AmpC detection mix  
The bla AmpC detection mix for the samples consisted of 
i. probe PCR master mix 10µl 
ii. AmpC/internal control primer probe mix 10µl, 
iii. purified DNA sample 5µl ,a total volume of 25µl.(Table.4.2)  
For positive control mix, 5µl of positive control template was added 
instead of sample DNA and for negative control mix, 5µl of nuclease free 
water was added instead of sample DNA.(Table 3& 4)To prevent cross 
contamination, initially negative control, followed by samples and finally 
positive control was added. After adding all the ingredients, they were 
centrifuged and placed in the thermo cycler for PCR reaction to occur.
Table.2. bla AmpC detection mix for samples 
S.No Components Volume 
1. Probe PCR Master Mix 10µl 
2. 
AmpC /Internal Control Primer  
Probe Mix 
10µl 
3. Purified DNA sample 5µl 
4. Total reaction volume 25µl 
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Table.3:bla AmpC Positive control mix 
S.No Components Volume 
1. Probe PCR Master Mix 10µl 
2. 
AmpC/Internal Control Primer Probe 
Mix 
10µl 
3. Positive control template 5µl 
4. Total reaction volume 25µl 
 
Table:4. bla AmpC Negative control mix 
S.No Components Volume 
1. Probe PCR Master Mix 10µl 
2. 
AmpC/Internal Control Primer  Probe 
Mix 
10µl 
3. Negative control template 5µl 
4. Total reaction volume 25µl 
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4.4.8.Basic steps in amplification 
For initial denaturation for Taq enzyme activation, the temperature is 
increased to 95˚C for five minutes initially. 
Denaturation- By increasing the temperature 95˚C for 20 seconds, template 
DNA strand issplit in to two complementary strands. 
Annealing- By decreasing the temperature to 55˚C for 20 seconds, two specific 
oligonucleotide primers get attached to the DNA template complementarily. 
Extension- Increasing the temperature to 72˚C for 20 seconds, each primer is 
extended by DNA polymerase at the 3‟ terminus and the complementary strands 
are synthesized along 5‟ to 3‟ terminus of each template DNA using 
deoxynucleotides in the reaction mixture.  
Then two double stranded DNA copies are produced by allowing single 
template DNA strands to bind with the complementary DNA strands . 
 To amplify further, each copy of DNA is used as template. The doubling 
of products in every cycle for a total of 40 cycles leads to final PCR products 
having 2n copies of template DNA.  Data collection was made at the end of 
extension and the computer produces the cross threshold (Ct) value by 
calculating the fluorescence emitted at the end of each cycle. (Table 5) 
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Table.5.Amplification profile for bla AmpC gene 
` 
Step Time Temp 
Taq enzyme activation 5min 95
0
 C 
 
40cycles 
Denaturation 20sec 95
0
 C 
Annealing/ Data collection 20sec 55
0
 C 
Extension 20sec 72
0
 C 
 
 
Ct value   
When Ct value was less than 38, it was considered as positive for bla 
AmpC gene. 
Samples that cross the threshold line at or after 38 cycles, should be retested.. 
(Table 6) 
Negative result if no amplification occured. 
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Table.6 Interpretation of results 
Test 
Sample 
Negative 
control 
Internal 
control 
Positive 
control 
Interpretation 
+ ve -ve 
+ ve + ve 
+ ve 
- ve -ve + ve + ve 
-ve 
- ve -ve 
- ve - ve Repeat 
Positive Positive Positive Positive Repeat 
 
 
 
 
 
 
 
 
 
 
 
4.Colony appearance of E.coli on MacConkey agar 
 
5. Colony appearance of Klebsiella pneumoniae on 
MacConkey agar 
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5. RESULTS 
5.1. Study samples 
The study was undertaken in Clinical microbiology laboratory of 
Tirunelveli Medical College, Tirunelveli for a period of one year between April 
2013 to May 2014. A total of 50 (urine[n=45], pus[n=5]) non-duplicate 
Cefoxitin resistant Gram negative isolates from clinical samples which included 
E.coli(n=23), Klebsiella pneumoniae(n=21 ), Klebsiella oxytoca(n= 6) were 
taken for this study. Modified Hodge test and AmpC disc test were done on the 
strains and detection of bla AmpC was done by Real-Time PCR. The risk 
factors and antibiotic sensitivity patterns of the isolates were further analysed. 
5.2. Statistical Analysis  
Data regarding the subjects were described in terms of percentages. The 
susceptibility, resistant and intermediately susceptible were described in terms 
of percentages. The statistical analysis was done using with the help of the IBM 
SPSS statistics 20. Chi square test, Fischer exact test and Mcnemer test were 
used to find out „p‟ value. If the p value is less than 0.05 ,it is significant 
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5.3. Analysis by age and sex 
Table- 7: Sample distribution by age and sex 
Age (years) 
Male Female Total 
No % No % No % 
≤ 15 1 4.2 3 11.5 4 8 
16 – 30 2 8.3 5 19.2 7 14 
31 – 45 5 20.8 1 3.8 6 12 
46 – 60 6 25 10 38.5 16 32 
≥61 10 41.6 7 26.9 17 34 
Total 24 100 26 100 50 100 
  
Out of Cefoxitin Resistant 50 isolates, 24 isolates (48%) were from males 
and the remaining 26 isolates (52%) were from females. A total of 4 (8%) 
isolates, fell in the study group of ≤ 15 years of which, 1 isolate (4.2%) was 
from male and 3 isolates (11.5%) were from females. Out of the 7 (14%) 
isolates in the 16-30 years age group, two isolates (8.3%) were from males and 
five isolates (19.2%) were from females. A total of 6 (12%) isolates were in the 
31-45 age group, of which, five isolates (20.8%)were from males and one 
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isolate (3.84%) were from females. A total of 16(32%) isolates were in the 46-
60 years group, out of which six isolates (25%) were from males and ten 
isolates (38.5%) were from females. Out of seventeen isolates in persons above 
61 years, ten isolates (41.6%) were from males and seven isolate (26.9%) were 
from females(Table:7).  
Fig – 15 : Analysis of samples by age and sex 
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5.4:Analysis of various methods for AmpC detection 
Table- 8: Comparison of MHT and AmpC disc test 
 
Method 
AmpC Positive AmpC Negative 
No % No % 
MHT 16 32 34 68 
AmpC disc test 18 36 32 64 
 
 
All the 50 Cefoxitin resistant isolates were evaluated for AmpC enzyme 
production by Modified Hodge test and AmpC disc test.Of these,16 gave 
positive results by MHT and 18 gave positive results by AmpC disc test. 
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Figure-16:Comparison of MHT and AmpC disc test 
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5.5: Prevalence of bla AmpC among Cefoxitin resistant isolates 
Table -9: Prevalence of bla AmpC among Cefoxitin resistant isolates 
 
 PCR CRI % 
Positive 21 42 
Negative 29 58 
Total 50 100 
 
Among the 50 cefoxitin resistant isolates, bla AmpC was present in 
twenty one (52 %) by Real Time-PCR.  (Table. 9). 
 
Figure: 17. Prevalence of bla AmpC among Cefoxitin resistant isolates 
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5.4. Distribution of positive isolates by MHT,AmpC disc test and PCR 
 
Table .10 Distribution of positive isolates by MHT,AmpC disc test 
and PCR 
 
 
Positive  
Isolate 
E.coli K.pneumo
niae 
K.oxytoca 
MHT 8(34.8%) 8(38.1%) 0 
AmpC 
disc test 
10(43.5%) 7(33.3%) 1(16.7%) 
PCR 11(47.8%) 10(47.6%) 0 
 
 
Among 16 MHT positive isolates,eight isolates(34.8%) were E.coli and 
another 8 isolates(38.1%) were Klebsiella pneumoniae. Among eighteen AmpC 
disc test positive isolates,ten isolates(43.5%) belong to E.coli and seven 
isolates(33.3%) were Klebsiella pneumoniae,One isolate(16.7%) was Klebsiella 
oxytoca.Eleven isolates(47.8%) were E.coli and ten isolates(47.6%) were 
Klebsiella pneumoniae among the 21 PCR positive isolates. 
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Figure.18. .Distribution of positive isolates by MHT,AmpC disc test,PCR 
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5.7. Correlation of MHT and PCR 
 
Table- 11: Comparison of MHT and PCR 
 
MHT 
PCR  
Positive Negative 
Positive 15 1 
Negative 6 28 
Total 21 29 
 
 
The sensitivity, specificity of MHT were 71.42%, 96.55%, and   positive 
predictive value and negative predictive value of MHT were 93.75% and 
82.35% respectively.(Table :13)According to Mcnemar test(Value-0.375), 
Modified hodge test is not more sensitive than PCR(Gold standard). 
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5.8. Correlation of AmpC disc test and PCR 
 
Table -12: Comparison of AmpC disc test and PCR 
 
AmpC disc test 
PCR  
Positive Negative 
Positive 17 1 
Negative 4 28 
Total 21 29 
 
 
The sensitivity, specificity of AmpC disc test were 80.95%, 96.55% and 
positive predictive value and negative predictive value were 94.44% and 
87.55% respectively in AmpC disc test. (Table 14)According to Mcnemar 
test(value-0.375), AmpC disc test is not more sensitive than PCR(Gold 
standard) 
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5.9. Distribution of bla AmpC gene positive isolates by age and gender  
 
Table 13: bla AmpC gene positive isolates by age and gender 
 
 
 
 
 
 
 
 
 
 
  
Table 13 shows the distribution of PCR positive isolates by age and 
gender distribution. Most of the PCR positive isolates (57.14%) were from 
females. In the age group of   below 15 years, two isolates (16.66%) were from  
females, no males were in this group. One isolate (11.11%) was from male and 
two  females(16.66) were in the 16-30 years age group. In the 31-45 years age 
group, two isolates (22.22%) were from males and no females were in this 
group. Above 61 years four isolates (44.44%) were from males.(Figure.19 
Age 
in years 
PCR positive isolates 
Male Female 
No % No (%) 
≤ 15 0 0 2 16.66 
16 – 30 1 11.11 2 16.66 
31 – 45 2 22.22 0 O 
46 – 60 2 22.22 4 33.33 
≥61 4 44.44 4 33.33 
Total 9 42.85 12 57.14 
76 
 
&Table .13) The mean age of female was 46.3 years and that of male was 53.7 
years among AmpC positive isolates. 
 
 
Figure:19: Distribution of bla AmpC gene positive isolates by age and sex 
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5.10. Distribution of bla AmpCgene positive isolates among various samples 
  
Table- 14: Distribution of bla AmpCgene positive isolates among various 
samples 
 
Samples 
AmpC positive AmpC negative 
No % No % 
Urine 
 
20 95.2 25 86.2 
Pus 
 
1 4.8 4 13.8 
Total 
 
21 100 29 100 
 
 
Among 21 AmpC positive isolates,20(95.2%) were isolated from Urine 
samples and one isolate (4.8) from pus.  
Among 29 AmpC negative isolates,25(86.2%) were isolated from Urine 
samples and four  isolates(13.8) from pus (Table-14) 
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Figure- 20: Distribution of bla AmpC gene positive isolates among various 
samples 
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5.11: Association of  bla AmpC gene  producers with infections 
 
Table- 15:Categorization of bla AmpC gene  producers on infection basis 
 
 
Infections 
AmpC producers 
AmpC non 
producers 
No % No % 
Surgical site infection 1 4.8 2 6.9 
Wound infection 0 0 2 6.9 
Obstructive uropathy 6 28.6 1 3.4 
Urinary tract infections 14 66.7 24 82.6 
Total 21 100 29 100 
 
 
In the present study, majority of the AmpC producers are associated with 
urinary tract infections i.e. 14 (66.7%). One isolate was recovered from surgical 
site infection (4.8%), Six isolates(28.6) from obstructive uropathy cases. (Fig.21 
& Tab.15) 
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Fig -21: Association of infections with of bla AmpC gene  producers 
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5.12. Risk factors: 
5.12.1. Device related infections 
 
Table -16: Association of catheterization with bla AmpC gene producers 
among urine samples 
 
 
 
 
 
 
 
Urine samples for 75%of AmpC producers and 25 % of AmpC non producers 
were obtained from catheterized patients. There was a statistically significant 
association between catheterization and AmpC producers in urine samples. 
(P = 0.0001) (Tab.16 & Fig. 22) 
 
Risk factors 
AmpC producers 
AmpC non 
producers 
No % No % 
Catheterized 15 75 5 20 
Not catheterized 5 25 20 80 
Total 20 100 25 100 
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Figure- 22:Association of catheterization with with bla AmpC gene  
producers among urine samples 
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5.12.2. Duration of hospital stay  
              
Table- 17:Duration of hospital stay among AmpC positive isolates 
            
 
 
 
 
 
 
 
A total of four(19.04%) and seventeen (80.95%) of the AmpC positive 
isolates were from patients with less than 15 days stay in hospital and more than 
15 days respectively.The association of AmpC positive isolates with the 
duration of stay in hospital was statistically significant [P < 0.05] (Table.17 & 
fig.23)  
 
 
 
 
 
Duration in 
days 
AmpC producers AmpC non producers 
No % No % 
>15 17 80.95 6 20.7 
<15 4 19.04 23 79.31 
Total 21 100 29 100 
84 
 
 
Fig – 23:AmpC positive isolates by duration of hospital stay 
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5.12.3. Exposure to antibiotics:  
Table -18: Adminstration of Antibiotics among AmpC positive and AmpC 
negative isolates 
  
Antibiotics 
AmpC 
producers 
AmpC non 
producers 
Significance 
P<0.05 
Recieved % Recieved %  
Cephalosporins 16 76 6 21 Significant 
Amikacin 1 5 6 21 Not Significant 
Norfloxacin 2 10 8 28 Not Significant 
Imipenem 2 10 1 3.4 Not Significant 
 
A total of sixteen (76%) patients had received third generation 
Cephalosporins among AmpC positive isolates.One (5%) patient had received 
aminoglycosides among AmpC positive isolates.A total of 2 (10%) patients had 
received fluoroquinolones among corresponding AmpC positive isolates. 
Totally two patients (10%) had received carbapenems among AmpC positive 
isolates.There was statistically significant difference in exposure to third 
generation Cephalosporins among AmpC positive and AmpC negative isolates. 
(P <0.05) (Tab.18 & Fig.24) 
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Figure- 24: Administration of Antibiotics among AmpC positive 
and AmpC negative isolates 
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5.13. Antibiotic   Susceptibility pattern of bla AmpC positive and  blaAmpC 
negative isolates : 
Table-19: Antibiotic Susceptibility pattern of bla AmpC positive and  bla 
AmpC negative isolates 
 
Susceptibility 
AmpC 
producers 
AmpC non 
producers 
Significance 
P<0.05 
R % R %  
Amikacin 9 43 4 14 Significant 
Gentamicin 17 81 18 62 Not Significant 
Norfloxacin 16 80 8 32 Significant 
Nitrofurantoin 15 75 10 40 Significant 
Cephalosporins 21 100 29 100 Not Significant 
Carbapenems 0 0 0 0 - 
 
Resistance to Amikacin was noted among 9 (43%) AmpC positive and 
4(14%) AmpC negative isolates. Among 20 AmpC positive and 25AmpC 
negative urine isolates, 15 (75%) isolates &10(40%) were resistant to 
Nitrofurantoin.A total of 16 (80%) AmpC positive urine isolates and eight  
88 
 
(32 %) AmpC negative isolates were resistant to Norfloxacin (5µg). Among the 
AmpC positive and AmpC negative isolates, seventeen (81%) &18(62%)were 
resistant to Gentamicin ,  
In AmpC-positive and AmpC negative isolates, the resistance to third 
generation Cephalosporins was high, reaching 100% for ceftriaxone and 
ceftazidime and ceftazidime+clavulanic acid. All the isolates were sensitive 
(100%) to Imepenem (10µg) and none of them were resistant to the drug among 
AmpC positive and AmpC negative isolates.(Table:20,Figure: 26) 
There was statistically significant difference in the susceptibility pattern of 
Amikacin,Nitrofurantoin, Norfloxacin among AmpC positive and AmpC 
negative isolates(P<0.05).   
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Figure-25: Antibiotic Susceptibility pattern of bla AmpC positive and bla 
AmpC negative isolates
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6. DISCUSSION 
 
 In the past few decades there has been a rise in the incidence of resistance 
to β-lactam antibiotics in bacterial pathogens.Among the various resistance 
mechanisms, production of β-lactamases is the most widespread and effective 
mechanism . Plasmid mediated AmpC-β-lactamase is a new threat worldwide as 
they mediate resistance to a broad spectrum of antibiotics. Among the 
Enterobacteriaceae family, Klebsiella pneumoniae and E.Coli which produce 
plasmid-mediated AmpC β-lactamases are responsible for nosocomial outbreaks 
of infection and colonization. As there are no CLSI guidelines, detection of 
AmpC β-lactamases is a challenge to microbiological laboratories and molecular 
detection is not also possible in all laboratories.However, proper recognition of 
AmpC producing E. coli and Klebsiella species is important for clinical 
management and epidemiological surveillance. 
71.
 
6.1. Phenotypic methods: 
Various range of tests from enzyme extraction methods have been 
described in the literature,but these are consuming too much of time and 
difficult for routine use. Inhibitor based tests are also have been reported , but 
these inhibitors may not be readily available. So, simple methods by using 
available materials are used to detect AmpC enzyme in this study. 
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6.1.1. Modified hodge test and AmpC disk test: 
All the 50 cefoxitin insusceptible isolates were evaluated by Modified 
hodge test and AmpC disk test for the production of AmpC enzyme. Of these, 
16 and 18 isolates were positive by MHT and AmpC disk test respectively. 
Among 16 MHT positive isolates ,eight isolates(34.8%) were E.coli and another 
8 isolates(38.1%) were Klebsiella pneumoniae. Similarly, Neelam Taneja et 
al
5
observed that 40% of  E.coli  isolates  were positive for AmpC enzyme 
production by MHT. 
Among eighteen AmpC disc test positive isolates,ten isolates(43.5%) 
belong to E.coli and seven isolates(33.3%) were Klebsiella pneumoniae,One 
isolate(16.7%) was Klebsiella oxytoca.Smitha O. Bagali et al
78
 and Vijaya 
Shivanna et al
74
denoted that 24% and 20%of E.coli  isolates  were positive for 
AmpC enzyme production by AmpC disc test respectively. 
6.2. Molecular methods: 
Detection of bla ampC Gene(CMY-2) by RT-PCR 
The advantages of molecular methods over phenotypic methods are 
identification of multiple AmpC gene types and shorter detection time. 
However, molecular methods may miss unusual gene types and require trained 
personnel and costlier equipments. For the identification of blaAmpC gene, 
Polymerase chain reaction have been used principally in research laboratories 
and reference centers. Goerge A jacoby et al concluded that multiplex PCR was 
the current “gold standard” for plasmid-mediated AmpC β lactamase detection.9 
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 In this study, bla AmpC(CMY-2) was present in twenty one of fifty 
(42%) Cefoxitin resistant isolates. Similarly, various observations by Tanushree 
banu et al 
16
, Ty.Tan et al
11
,Mai m helmy et al
89
 Tenover et al
85
have  observed 
that CMY-2 subtype of AmpC β-lactamases are the predominant type in  E. coli 
and Klebsiella  isolates. 
6.3. Comparison of Phenotypic methods with molecular methods 
Detection of AmpC enzyme by MHT and AmpC disc test were evaluated 
for sensitivity and specificity against RT-PCR as reference test .In the present 
study, the sensitivity and specificity of MHT were 71.42%and 96.55% 
respectively and the sensitivity of AmpC disc test was 81% and specificity was 
96.55%. Similarly, Paul et al reported that Sensitivity of MHT was 73%and 
Specificity of MHT was 95%,and the sensitivity & specificity of AmpC disc test 
were  86% and 94%respectively. 
14
 
 R.K.Manojkumar et al (Imphal) have observed that the sensitivity of 
AmpC disc test was 73.9%.
88
In contrast, another study by Yong D et al
79
 
reported that the sensitivity and specificity of the MHT were 100% and 94.9%, 
respectively. 
In current study, AmpC disc test identified more positives than MHT. 
Similarly Tanushree banu et al found  that the correlation between the AmpC 
disk test and the modified Hodge test is not perfect and the AmpC disk test 
identified more positives in their subset of isolates .
16
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Sometimes MHT shows false negative with AmpC producers as MHT 
uses integral cells, which may not liberate β-lactamases as efficiently.18It was 
found that the sensitivity of the Amp C disk test was more (81%) when 
compared to MHT(71.4%)and this test was a simple, convenient test and 
required no special inhibitors. The present study suggests that the AmpC disc 
test may be used for routine detection of the AmpC β lactamase in a clinical 
laboratory where the molecular methods are not available. But Phenotypic tests 
do not differentiate between chromosomal AmpC genes and plasmid mediated 
AmpC genes. Hence, genotypic characterization is considered as the gold 
standard .
71
 
6.4. Prevalence of bla AmpC gene   
In the present study, the prevalence of AmpC producers was 47.8% in 
E.coli and 47.6% in Klebsiella pneumoniae among the 50 Cefoxitin resistant 
clinical isolates by PCR . This is comparable with the study done by Akujobi et 
al
4 
from Nigeria who reported that the prevalence of AmpC in E.coli and 
Klebsiella pneumoniae isolates was up to 56.25% and43.75% respectively in 
2012.Similarly, Şerife Altunet al58 from Turkey in 2013  found that 33% of  
E.coli and 46.7% of  Klebsiella pneumoniae  isolates were positive for                       
blaAmpC gene. Parveen R. Mohamudha
71
(Puducherry) reported that the 
prevalence of AmpC production in E. coli and K.pneumoniae isolates was 
68.5% and 31.4% respectively in 2010.
71
 Similarly, Sridhar Rao PN et al 
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77
(Karnataka) reported 48.38% of E.coli and 59.1% of Klebsiella pneumoniae as 
AmpC β lactamase enzyme  producers in 2006.77 
R.K. Manojkumar Singh et al (2011)from Imphal observed that the 
prevalence of AmpC β lactamase production in E. coli and K.pnumoniae 
isolates was 29.2%and22.9% respectively which was lower than the prevalence 
obtained by the present study.
88 
The high prevalence of AmpC producers in our 
study is due to exposure of previous cephalosporin therapy whether empirically 
or according to the hospital antibiotic policy. 
6.5. Distribution of bla AmpC positive isolates according to age and gender 
 In this study, most of the isolates (57.14%) were from females. The mean 
age of female was 46.3 years and that of male was 53.7 years among AmpC 
positive isolates. Similarly, Sasirekha et al (2013) reported that 69.3 % of the 
AmpC producing pathogens were from females .
32
 
6.6. Distribution of bla AmpC positive isolates according to site of infection  
Majority of the infections were associated with urinary tract infections i.e. 
14 (66.7%). one isolate from surgical site infection (4.8%), six isolates ( 28.6 
%) from Obstructive uropathy cases. The same distribution was noted in various 
observations done by  T.y.Tan et al
 11
, Slike polsfusset al
61
 and Nevine Fam  et 
al,
63
 Smitha O. Bagali et al
78
 who have concluded that the majority of the 
AmpC producing pathogens were isolated from urine. B.L.Chaudhary et al 
(2013) reported that the prevalence of AmpC positive isolate was highest in Pus 
(52.63%) followed by urine (7.40%). This is contrast to the present study. 
75
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6.7. Risk factors  
6.7.1. Device related infections  
In the present study, there was a statistically significant association 
between catheterization and AmpC producers. Neelam taneja et al
5
in 
2008(North india)  found that inserting Foley‟s catheter is a risk factor for 
AmpC associated infections. Goerge A jocoby et al from Israel in 2009 also 
found that Foley‟s catheter insertion  is  a definite risk factor for AmpC 
associated infection.
9 
6.7.2. Duration of hospital stay
 
In this study, all AmpC positive (100%) strains were from inpatients and 
80.95% of AmpC positive isolates were from patients with more than fifteen 
days stay in hospital .There was a statistically  significant association between 
hospital stay and AmpC production. Similarly, Kenneth h rond et al observed 
that the hospital stay of AmpC positive patients was significantly longer than 
patients in the control group.(P = .047) 
18  
Similarly, Various studies by Vikas Manchanda et al
67
, 
Chakraburtyetal
87
, Rajesh pareja et al 
76
who reported that AmpC positive 
isolates were mainly limited to hospitalized patients only. 
 
But in contrast , one observation by Goerge A jacoby et al have reported 
that AmpC producers were also isolated from outpatient clinics, which indicate 
the presence of AmpC in the community .
9 
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6.7.3. Antibiotic usage  
An extensive use of β-lactam antibiotics in hospital and community has 
produced a major problem leading to increased morbidity, mortality and health 
care costs. Exposure to different classes of antibiotics like third generation 
Cephalosporins, Aminoglycosides, Fluoroquinolones, Nitrofurantoin and 
Carbapenems were analysed among AmpC positive and AmpC negative 
patients. 
Among these antibiotics, exposure to Cephalosporins was statistically 
significant among corresponding AmpC positive patients. The high prevalence 
of AmpC producers in our study is due to exposure of previous Cephalosporin 
therapy whether empirically or according to the hospital antibiotic policy. 
Similar reports are available from various studies by Goerge A chocoby et 
al
9
,Nevine fam et al
63
and they have confirmed that prior management with 
antibiotics, particularly combinations of Cephalosporins and β-lactamase 
inhibitors are significantly associated with infection by AmpC positive isolates.  
Arindam Chakraborty et al
87
 reported that combining Cephalosporins  
with Penicillins and addition of β lactam with a β-lactamase inhibitor are 
potential risk factors for AmpC induction. Limited use of antimicrobial agents, 
predominantly, broad-spectrum Cephalosporins,β-lactamase inhibitor 
combinations, Fluoroquinolones are suggested to prevent AmpC associated 
infection.Prolonged antibiotic treatment should be avoided. 
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6.8.   Multidrug   resistance:  
In AmpC-positive isolates, the resistance to third generation 
Cephalosporins was high, reaching 100% for Cefotaxime and Ceftazidime and 
Ceftazidime+Clavulanic acid and they were resistant to Amikacin, Gentamicin, 
Nitrofurantoin and Norfloxacin in 42.9%, 81%,75% and 80% respectively.  
 AmpC-negative isolates were resistant to Cephalosporins i.e.100% to 
Cefotaxime, Ceftazidime and Ceftazidime+Clavulanic acid and13.8%, 
62.1%,40% and32% were resistant to Amikacin, Gentamicin, Nitrofurantoin 
and Norfloxacin  respectively. This is in accordance with the studies by Nevine 
fam et al,
90 
Deepika handa et al 
70
Who observed that the AmpC positive isolates 
showed high resistance to third generation Cephalosporins( 100% ). In contrast, 
Kenneth H rond et al reported that 36%and 56% of their AmpC-producing 
isolates were reported as susceptible to Cefotaxime and Ceftazidime, 
respectively.
18
In the current study, AmpC-positive isolates showed resistance to 
Norfloxacin (80%) and to Amikacin (42.9%)which were lower than those 
reported (94.1% and41.2% respectively)by Nevine fam et al.2008. In contrast, 
Deepika handa et al (Utthrapradesh-2007) observed that resistance among the 
AmpC positive isolates to Norfloxacin and Amikacin were 66.7% and 20.8% 
respectively.
70
 
Similarly, Arindam chakraborty et al
87
 in 2010 demonstrated that AmpC 
producers were multidrug resistant, with Amikacin- 40%, Gentamcin- 73%, 
Norfloxacin- 51%.  
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Fortunately all isolates retained susceptibility to Imipenem. It is in 
accordance with other studies by Varsha gupta et al, V.Hemalatha et al
69
, 
Mohammad Soltan Dallalol et al
91 
who reported that the susceptibility pattern of 
their isolates showed100 per cent susceptibility to Imipenem. 
Amikacin is the second most common sensitive drug after Imipenem. So, 
these drug resistant organisms have limited therapeutic options and necessitated 
the increased use of Carbapenems.  
In the present study, MDR among AmpC positive isolates was 33.3% 
which is due to plasmid mediated spread. Similarly, Arindam chakraborty et al
87
 
in 2010 demonstrated that 35% of AmpC producers were multidrug resistant. 
In contrast, Mohammad Soltan Dallalol et al found that 70% of the 
AmpC positive isolates exhibited a multidrug resistance phenotype.
91
 
6.9. Treatment   
In the present study, it was found that treatment with Carbapenems was 
successful in nineteen(90.5%) of the corresponding AmpC positive patients.  
This is in accordance with the studies by Mai me helme et al
89
, 
Neelam taneja et al suggested that Imipenem and Meropenem were the 
best treatment option in treating serious infections caused by AmpC producing 
isolates.In the current study,two patients(9.5%) had received Norfloxacin who 
were diagnosed to have urinary tract infection. Similarly, Arindam Chakraborty 
et al suggested treatment of patients infected with AmpC producing isolates 
using Carbapenems and Aminoglycosides .
87
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Smitha O. Bagali et al concluded that Carbapenems are drug of choice for 
AmpC producing bacteria but resistance to Carbapenem may arise by mutation 
which diminish influx or augment efflux.
78 
In this study, 58% of cefoxitin resistant isolates were not positive for 
AmpC production by PCR and this warrants further investigation into the other 
mechanisms of resistance and their laboratory detection. Many factors may 
explain resistance to cefoxitin in the AmpC-negative isolates. 
 In this study, twenty one isolates were positive for CMY-2 gene  
detected by RT PCR. The remaining 29 PCR negative isolates 
might contain other genes of AmpC(MOX, DHA, EBC, FOX and 
ACC-1).  
 It may be due to porin channel alterations and mutations in E. coli 
and Klebsiella isolates.  
 Cefoxitin resistant in E. coli may effect from over expression of the 
chromosomal mediated ampC gene which results in changes in the 
permeability of the cell to Cefoxitin.
90
 
6.10. Prevention  
 Enhanced sanitary measures in the outpatient setting, restriction of patient 
transfer between healthcare facilities, active viewing of patients transferred 
from a high-risk institution and cohorting for already colonized patients are 
recommended for the prevention of AmpC colonization and infection. Increased 
100 
 
accurateness in the recognition of resistance mechanisms will be effective in 
planning infection control and treatment guidelines.
56
 
Dissemination of AmpC producers within the hospital or between the 
different regions of our country may become significant public health issue. 
Hence, recognition of AmpC may enhance hospital infection control rate by 
making the physician to think about the selection of suitable antibiotics.
 18
 The 
sensitivity of the AmpC disc test was more (81%) when compared to 
MHT(71.4%).Hence, this AmpC disc test may be used for routine detection of 
the AmpC β lactamase in a clinical laboratory where the molecular methods are 
not available. 
Findings of this study designate the necessity for sustained observation of 
mechanisms of resistance among nosocomial pathogens and evolving 
preventive measures aimed at reducing their spread.
13
 The information from this 
study would be helpful for formulation of an antibiotic policy for its rational 
use.
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7. SUMMARY 
This study was undertaken at Tirunelveli Medical College, Tirunelveli for a 
period of one year from 50 cefoxitin resistant clinical isolates of 
Enterobacteriaceae . Modified Hodge test and AmpC disc test were done to 
detect AmpC enzyme production and isolates were also tested for blaAmpC 
gene by Real-Time PCR. The risk factors and antibiotic sensitivity patterns of 
the isolates were further analysed. 
 A total of 24(48%) isolates were from males and the remaining 26(52%) 
were from females. 
 Modified Hodge test detected 16 (32%)AmpC positive isolates indicated 
by clover leaf pattern.Among these ,eight isolates(34.8%) were E.coli and 
another eight isolates(38.1) were Klebsiella pneumoniae.  
 AmpC disc test detected 18 AmpC positive isolates.Among these,ten 
isolates(43.5%) were E.coli and seven isolates(33.3%) were Klebsiella 
pneumoniae , one isolate(16.6%) was Klebsiella oxytoca. 
 Real time PCR detected bla AmpC gene in twenty one (42%) of the 50 
screen positive isolates .Among these,eleven isolates (47.8%)were E.coli, 
10 isolates(47.6%) were Klebsiella  pneumoniae. 
 The sensitivity, specificity of Modified hodge test were 71.42%, 96.55%, 
and PPV and NPV were 93.75% and 83.53% respectively.  
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 The sensitivity, specificity of AmpC disc test were 80.95%, 96.55%, and 
PPV and NPV were 94.44% and 87.5% respectively. 
 A total of 57.14% of the AmpC positive isolates were from females and 
42.85% were from males. 
 Majority of the AmpC producers are associated with urinary tract 
infections i.e. 14 (66.7%). One isolate was recovered from surgical site 
infection (4.8%), Six isolates(28.6) from obstructive uropathy cases.  
 Duration of stay at hospital for more than fifteen days was statistically 
significant among corresponding AmpC positive patients. 
 There was a statistically significant association between catheterization 
and AmpC production in urine samples. 
 Exposure to Cephalosporins was statistically significant among  
corresponding AmpC positive patients.. 
 In AmpC-positive isolates, the resistance to third generation 
Cephalosporins was high, reaching 100% for Ceftriaxone and 
Ceftazidime and Ceftazidime+clavulanic acid and were resistant in 43%, 
81%,75% and 80%  respectively to Amikacin, Gentamicin, 
Nitrofurantoin and Norfloxacin . 
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8. CONCLUSION 
 
 This study highlights the prevalence of AmpC enzyme production among 
clinical samples and also bla AmpC among AmpC producers. 
 Modified Hodge test is simple to do and less costlier. 
 AmpC disc test is to be considered as a diagnostic tool for AmpC 
detection in routine laboratory because of its high sensitivity, rapid and 
easy interpretation. 
 In the present study, MDR among AmpC positive study isolates was high 
suggesting plasmid mediated  spread . 
 Carbapenems are superior to other antibiotics for the treatment of serious 
infections due to AmpC β lactamase-producing gram-negative bacteria. 
 An approach to eradicate AmpC producers in the hospitals is to create 
awareness among health care workers and following effective barrier 
precautions and good hygienic practices to prevent further transmission. 
Dissemination of AmpC producers within the hospital or between the 
different regions of our country may become significant public health 
issue. Hence, recognition ofAmpC may enhance hospital infection control 
rate by making the physician to think about the selection of suitable 
antibiotics. 
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10.ANNEXURE-1 
1.Preparation of Media 
Nutrient agar medium 
Composition 
Ingredients gram/liter 
Peptone               - 5.00 
Sodium Chloride- 5.00 
Meat  Extract       - 10 
Agar                      -15.00 
Twenty-eight grams of dehydrated nutrient agar medium was added 
to 1000 ml of cold distilled water in a flask and boiled to dissolve the 
medium completely. The medium was then sterilized in an autoclave at 
1210C and 15 lbs pressure for 15 minutes. The sterile media were stored in 
a refrigerator at 40C for future use. 
Blood agar medium 
Composition 
Ingredients gram/liter 
Heart infusion 500.00 
Tryptose 10.00 
Sodium chloride 5.00 
Agar 15.00 
Forty grams of the dehydrated blood agar medium was suspended in 1000 
ml cold distilled water in a flask and boiled to dissolve the medium 
completely. It was then sterilized by autoclaving at 1210C and 15 lbs 
pressure for 15 minutes. The autoclaved materials were allowed to cool to a 
temperature of 450C in a water bath. Defibrinated 5-10% sheep blood was 
then added to the medium aseptically and distributed to sterile petridishes. 
Sterile media was stored in refrigerator at 40C for future use. 
Muller Hinton agar medium 
Composition 
Ingredients gram/liter 
Beef dehytrated infusion- 300 
Casein hydrolysate          - 17.50 
Starch agar                        -1.5 
Agar                                   - 10.00 
Thirty-eight grams of dehydrated Mueller Hinton agar medium was 
suspended in 1000 ml cold distilled water and boiled to dissolve the medium 
completely. The solution was then sterilized by autoclaving at 1210C and 15 
lbs pressure for 15 minutes. The autoclaved media was stored at 4
0
C. 
MacConkey agar medium 
Composition 
Ingredients gram/liter 
Peptone 20.00 
Lactose 100ml(10% aqueous solution) 
NaCl 5.00 
Na-taurocholate 5.00 
Neutral Red 3.5ml(2% in 50%ethanol) 
Agar 20.00 
Fifty-two grams of dehydrated MacConkey agar medium was 
suspended in 1000 ml cold distilled water and boiled to dissolve the medium 
completely. The solution was then sterilized by autoclaving at 1210C and 15 
lbs pressure for 15 minutes. 
5. McFarland Standard (0.5): 
Reagents: 
Sulphuric acid,1%: To 100 ml of distilled water,1 ml of 
conc.sulphuric acid is added.Barium chloride, 1.175%: To 100 ml of 
distilled water, 1.175gm of barium chloride is added and mixed well. 
To prepare McFarland 0.5 standards: 
To 85 ml of 1% conc.sulphuric acid, 0.5 ml of Barium chloride is 
added in a flask while constantly swirling the flask. Bring to 100 ml with 
1% conc.sulphuric acid. Aliquot in test tubes and cap tubes tightly. Store in 
the dark   at room temperature for 3 months or longer. 
 
 
 
Physiological saline solution 
To make 1000 ml of Physiological saline solution, 0.9 gm of 
chemically pure sodium chloride was added in 1000 ml of distilled water in 
a sterile conical flask. The solution was then sterilized by autoclave at 
121
0
C maintaing a pressure of 15 lbs per square inch for 15 minutes. After 
sterilization, the sterile physiological saline solution was cooled and stored 
in a refrigerator at 4
0
C for future use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE -2     
PROFORMA 
Name    : 
Age    : 
Sex    : 
OP/IP No   : 
Lab No   : 
Ward    : 
Complaints   : 
Clinical diagnosis  : 
Nature of Specimen : Urine,Pus 
Duration of hospital stay : 
Antibiotics administered : 
Investigation  : 
Biochemical tests  :Indole,Citrate,Urease,Triple sugar iron, 
Catalase,Oxidase,Disc Diffusion test with  
Cefoxitin 
Modified hodge test 
AmpC   Disc Test 
PCR 
Antibiogram  : 
Ceftriaxone,Ceftazidime 
Ceftazidime with Clavulanicacid,Cefoxitin , 
Norfloxacin,Nitrofurantoin,Amikacin,Gentamicin 
Imipenem 
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K.P K.O Ward
1 109 35 M Ob.uro 20 U R R S R S R R R R p p P MERO P uro
2 136 26 M UTI 15 U R R S R R R S R R P P P ceftriaxone P Medicine
3 1087 57 F SSI 15 P R R S R S S R S R P P P ceftriaxone P childmed
4 134 24 F UTI 20 U R R S R R R R S R P P p Ceftriaxone P labour ward
5 7641 53 M UTI 15 U R R S S S R S R R P P P ceftriaxone P Medicine
6 1531 58 F UTI 17 U R R S R S R R R R N P p ceftriaxone P medicine
7 7939 65 F OB.uro 20 U R R S R S R R R R P P P Ceftriaxone P uro
8 8140 70 F UTI 10 U R R S R R S R R R N N N NOR P Medicine
9 8160 65 M UTI 10 U R R S R R R R S R N N N AMI P Medicine
10 8142 69 M UTI 15 U R R S R R S R R R N P P AMI P medicine
11 1085 66 M UTI 15 U R R S R R S R S R N P p NOR P Medicine
12 502 65 M Ob uro 15 U R R S R S S S S R N P N NOR p uro
13 733 57 M UTI 15 U R R S R S S R R R P P P ceftriaxone P Medicine
14 3 1 F UTI 15 U R R S R S R R R R N p P MERO P CHildmed
15 1310 52 F UTI 18 U R R S R R S R R R N p P CEFTZ P Medicine
16 1202 63 F Ob.uro 15 U R R S R R R R S R N p P NOR P Medicine
17 1228 80 F UTI 17 U R R S R R R S R R P P p ceftriaxone P SURGERY
18 1046 49 M UTI 7 U R R S R S R R S R N N N NOR P Medicine
19 8540 75 M UTI 10 U R R S R R R R R R P p P Ceftriaxone P Medicine
20 8382 23 F UTI 15 U R R S R S S R R R P N P CEFTZ P Labour ward
21 100 55 F UTI 7 U R R S R S R S S R N N N NOR P Medicine
22 101 22 F UTI 7 U R R S R S R S R R N N N MERO P Labour ward
23 77 38 M SSI 20 P R R S R S S R R R N N N AMI P SURGERY
24 18 2 M UTI 7 U R R S R S S R S R N N N NOR P childmed
25 111 65 F UTI 7 U R R S R S S S S R N N N AMI P Medicine
MASTER CHART
26 463 58 M UTI 5 U R R S R S S R S R N N N AMI P Medicine
27 131 47 F UTI 7 U R R S R S S S S R N N N AMI P uro
28 1131 36 M UTI 10 U R R S R S R R S R P N p ceftriaxone P Medicine
29 1832 2 F UTI 7 U R R S R S R R R R P N p ceftriaxone P childmed
30 7989 70 F UTI 5 U R R S R S R R R R P N p ceftriaxone P uro
31 8153 63 M OB,uro 7 U R R S R S S S S R P N N NOR P uro
32 7950 67 M UTI 15 U R R S R S R S R R P p P ceftriaxone p uro
33 1263 60 F UTI 15 U R R S R R R R R R P p P ceftriaxone p labour ward
34 5802 28 M UTI 7 U R R S R R S R R R N N N AMI P Medicine
35 31 43 M UTI 7 U R R S R S S S S R N N N NOR P Medicine
36 46 55 F Ob uro 5 U R R S R S S S S R N N N AMI P SURGERY
37 1272 37 F UTI 15 U R R S R S S R S R N N N ceftriaxone P SURGERY
38 1534 75 M UTI 10 U R R S R S R R S R N N N CEFTZ P SURGERY
39 7927 67 M .OB.uro 7 U R R S R R S R R R N N N AMI P uro
40 8002 60 F UTI 7 U R R S R S R R S R N N N ceftriaxone p Medicine
41 1140 37 M SSI 20 P R R S R S S R R R N N N ceftriaxone p SURGERY
42 8143 12 F wound inf 10 P R R S R S S R S R N N N AMI P childmed
43 717 50 M UTI 7 U R R S R S R R S R N N N AMI P Medicine
44 64 55 F Ob.uro 15 U R R S R S S S R R N N N CEFTZ P SURGERY
45 57 50 F UTI 7 U R R S R S R R S R N N N ceftriaxone p Medicine
46 2073 55 M UTI 15 U R R S R S S S R R N N N AMI P uro
47 1939 66 F wound inf 10 p R R S R S R S S R N N N AMI P SURGERY
48 1950 22 F UTI 10 U R R S R S S R R R N N N AMI P labour ward
49 2074 65 M UTI 7 U R R S R S R R S R N N N AMI P uro
50 1910 22 F UTI 10 U R R S R S R R R R N N N NOR P Medicine
